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ABSTRACT 
The work described in the thesis is based on the synthesis of heterocycHc 
compounds from cheap and readily available starting materials. The compounds 
chosen were 3-acetyl-4-hydroxycoumafin, 3-formyl-4-hydroxycoumarin, 6,7-
dimethyl-3-formyl-4-hydroxycoumarin, 5-chloro-3-methyl-1 -phenylpyrazole-4-
carboxaldehyde, 5-azido-3-methyl-l-phenylpyrazole-4-carboxaldehyde and 5-
amino -3-methyl-l -phenylpyrazole-4-carboxaldehyde. 
The reaction of 3-acetyl-4-hydroxycoumarin was carried out with 3-
formylchromone. The reaction afforded heterochalcone 56. Further 56 was treated 
with nitrogen bases such as hydrazine, phenylhydrazine and guanidine 
hydrochloride to afford novel heterocycles 58a, 58b and 60c' respectively. The 
structure of these compounds was inferred through spectral data. 
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3-Formyl-4-hydroxycoumarin and 6,7-dimethyl-3-formyl-4-hydroxy 
coumarin were readily converted to polyketomethylene compounds by treatment 
with triacetic acid lactone under different reaction conditions. This led to the 
formation of 68 and 69. The compounds 68 and 69 were transformed to pyrazole 
derivatives 70a, 70b, 70c, 71a, 71b, 71c and isoxazole 70d by treatment with 
nitrogen bases such as hydrazine hydrate, phenylhydrazine, hydrazine 
benzothiazole and hydroxylammonium sulfate. The structure of these compounds 
were established on the basis of spectroscopic studies and discussed at length in 
the thesis. 
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In another reaction 3-formyl-4-hydroxycoumarin was treated with active 
methylene compounds such as 5,5-dimethylcyclohexan-l,3-dione (dimedone) and 
3-methyi-l-phenyl-5-pyrazolone to give 74 and 78 respectively. The structure of 
these compounds was established through application of spectral data. 
H,C 
\ 
. ^ ^ ^ ^ CH, t ' 
N 0 0 N 
Ph Ph 
78 
In another set of reaction 5-chloro and 5-azido-3-methyl-l-phenylpyrazole-
4-carboxaldehyde were treated with triacetic acid lactone and 4-hydroxycoumarin. 
The reaction mixture afforded isomeric pyrones and benzopyrones viz. 94, 95 and 
96, 97 respectively. The structure of these compounds was determined on the basis 
of spectroscopic studies. 
/ ^ ^ 
HiC 
^^^^X 
96 97 
The reaction of 5-amino-3-methyl-l-phenylpyrazole-4-carboxaldehyde with 
triacetic acid lactone was carried out to get the expected product 105 involving 
translactonization type of rearrangement. The reaction however did not proceed as 
visualized and afforded rather unexpected product 106. 
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The structure of the compound 106 was established through the application of 
spectral data. 
The compounds (68, 70a, 70b, 70c and 106) were investigated for anti-
inflammatory, analgesic and antipyretic activities at the dose of 20 mg/kg 
body weight in animal models. These compounds were found to possess 
significant activities and their effect was compared with the standard drugs. 
In anti-inflammatory effect, the compounds inhibited formalin induced 
hind paw edema. The significant anti-inflammatory effect induced by the test 
compounds 70a, 70b, 70c and 106 appeared at 1-2 hrs, progressively 
increased, and reached 46.15, 88.46, 65.38 and 78,84% respectively at 5 hrs, while 
the maximum anti-inflammatory effect of test compound 68 appeared at 1 hr (60%). 
The anti-inflammatory effect induced by Diclofenac sodium (5 mg/kg) progressively 
increased and reached a maximum 70.83% at 2 hrs as compared to control. These 
compounds also significantly suppressed the formation of granuloma tissue in 
cotton pellet induced chronic model of inflammation. The test compounds and 
Diclofenac sodium significantly (P<0.05) reduced both wet weight as well as dry 
weight in cotton pellet granuloma as compared to control. The effect of test 
compound 70b in both reducing wet weight and dry weight of cotton pellet induced 
granuloma was similar to that of Diclofenac sodium. 
In analgesic test, the nociceptive response using hot plate test was 
performed in rats. The test compounds produced significant analgesic activity 
in hot plate test. The test compounds caused significant inhibition (P<0.05) of 
the neurogenic (early phase) and inflammatory phases (late phase) of formalin 
induced licking in rats. The Diclofenac sodium (5 mg/kg) also significantly inhibited 
formalin induced licking in rats but only in late phase (15-30 minute). In contrast, the 
reference antinociceptive drug Pentazocin (15 mg/kg) significantly reduced the 
licking activity against both phases of formalin-induced nociception. 
In the antipyretic tests, a model of pyrexia was used where baker's yeast 
(135 mg/kg) was used to induce pyrexia in rats. The test compounds (68, 70a, 
70b, 70c and 106) produced significant (P<0.05) antipyretic activity at 2 and 3 
hrs. Among these compounds 70a and the standard drug Paracetamol (150 
mg/kg) showed significant antipyretic activity throughout the observation 
period up to 5 hrs. These test compounds and Paracetamol were also tested on 
basal rectal temperature. The test compounds 68 and 70c were lowering of body 
temperature at 2 hrs (0.12 and 0.5 °C respectively) following its administration. While 
the maximum lowering of the rectal temperature noticed with the test compounds 70b 
and 106 were 0.2 and 0.25 °C respectively at 1 hr and that of compound 70a and 
Paracetamol were 0.1 and 0.05 °C at 1 and 3 hrs respectively. 
The compounds (68, 69, 70a, 70b, 70c, 70d, 71a, 71b, 71c, 74, 78 and 
106) were also screened for antibacterial activity against gram positive and 
gram negative bacteria using Disc diffusion method. The compound 106 
exhibited maximum antibacterial activity against both gram positive and gram 
negative bacteria (zone diameter 22 mm against Staphylococcus aureus, 22 mm 
against Escherichia coli, 15 mm against Pseudomonas aeruginosa, 18 mm against 
Salmonella typhi and 25 mm against Klebsiella pneumoniae as compared to 
antibiotic control Chloramphenicol (zone diameter 22, 23, Nil, 16, and 23 mm 
respectively). Other compounds exhibited moderate activity against both gram 
positive and gram negative bacteria. However, the compounds 71a and 71b 
did not show any antibacterial activity. 
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Introduction 
1. Introduction 
The work described in the thesis is based on the synthesis of heterocyclic 
compounds from cheap and readily available starting materials. The compounds 
selected were 3-acetyl-4-hydroxycoumarin, 3-formyl-4-hydroxycoumarin, 6,7-
dimethy 1-3-formyl-4-hydroxycoumarin, 5-chloro-3-methy 1-1 -phenylpyrazole-4-
carboxaldehyde, 5-azido-3-methyl-l-phenylpyrazole-4-carboxaldehyde and 5-
amino-3-methy 1-1 -phenylpyrazole-4-carboxaldehyde. 
In the first an attempt was made to synthesize new heterochalcone 
(2E)-1 -(4-hydroxy-1 -benzopyran-2-one-3-yl)-3-[ 1 ] (benzopyran-4-one-3-yl)-2-
propen-1-one 56 from 3-acetyl-4-hydroxycoumarin and 3-formylchromone. 
Further heterochalcone 56 was converted to pyrazoline derivatives by carrying 
out reaction in acetic acid with nitrogen bases such as hydrazine, 
phenylhydrazine and guanidine hydrochloride. The reaction mixture, as 
visualized, afforded 3-[4-hydroxy-[l]benzopyran-2-one-3-yr|-5-|5-(2-
hydroxylphenylpyrazol-4-yl]-pyrazolin 58a, l-phenyl-3-[4-hydroxy-[l] 
benzopyran-2-one-3-yi]-5-[5-(2-hydroxyphenyl)-l-phenylpyrazol-4-yl]-
pyrazolin 58b and 3-amino-l-(4-hydroxy-1-benzopyran-2-one-3-yl]-3-( 1-
benzopyran-4-one-3-yl)-propen-l-one 60c' respectively. 
In another series of reactions 3-formyl-4-hydroxycoumarin and 
6,7-dimethyl-3-formyl-4-hydroxycoumarin were readily converted to poly 
ketomethylenc compounds by treatment with triacetic acid lactone under 
different reaction conditions. This led to the formation of 3-acetoacctylpyrano 
[3.2-c] [IJ benzopyran-2,5-dione 68 and 8.9-dimelhyl-3-acetoacetylpyrano 
[3,2-c] f 1] benzopyran-2,5-dione 69. The polykctomethylcne compounds 68 
and 69 were transformed to pyrazole derivatives 3-(3-methylpyra/,ol-5-yl)-
pyrano |3 . 2-cJ 111 benzopyran-2,5-dione 70a, 3-(3-mctliyl-l-phenyl pyra/.olo-
yl)-pyrano [3, 2-cJ [IJ benzopyran-2, 5-dione 70b, 3-(3-methyl-l-
benzothiazolo pyrazol-5-yl)-pyrano [3,2-c] [1] benzopyran-2.5-dione 
70c, 8,9-dimethyl-3-(3-methylpyrazol-5-yl)-pyrano [3,2-c] [1 | benzopy 
ran-2,5-dione 71a, 8, 9-dimethyl-3-(3-methyl-l-phenylpyrazol-5-yi)-
pyrano[3,2-c][l]benzopyran-2,5-dione 71 b, 8,9-dimethyI-3-(3-methyI-I-
benzothiazoiopyrazoi-5-yi)-pyrano [3,2-c] [1] benzopyran-2,5-dione 71c 
and isoxazolc 3-(3-methyl isoxazol-5-yl)-pyrano L3.2-c] [1] benzopyran-2,5-
dione 70d b}' treatment with nitrogen bases such as hydrazine hydrate, 
phenylhydrazine, hydrazinobenzothiazole and hydroxylammonium sulfate. All 
these compounds were synthesized easily and in one step. In another set of 
reactions 3-formyl-4-hydroxycoumarin was treated with active methylene 
compounds such as 5,5-dimethylcyclohexan-l.3-dione (dimedone) and 3-
methyl-I-phenyl-5-pyrazolone to give 7-(4-hydroxycoumarin-3-yl)-IO.IO-
dimethyl-8-oxo-8,9.10.l 1-tetrahydro pyrano [3,2-c| coumarin 74 and 
methylidene-bis-4,4-(3-methyl-5-oxo-1 -phenylpyrazole) 78 respectively. 
Ihe reaction of 5-chloro-3-methyl-l-phenylpyrazolc-4-carboxaldehyde 
79 and 5-azido-3-mcthyl-l-phcnylpyrazole-4-carboxaldchyde 80 with cnol 
lactones such as triacctic acid lactone and 4-hydroxycoumarin were carried out 
under hydrolytic conditions, fhc reaction mixture afforded isomeric 
benzopyrones namely. 4-(4-hydroxy-6-melhyl-2-oxo-2Il-pyran-2-onc-3-
yl)-3.7-dimelhyl-l-phenylpyrazol() 13,4:2,3|-41I-pyran() |3.2-b| pyran-5-
one 94, 4-(4-hydroxy-6-melhyl-2-oxo-2H-pyran-2-onc-3-yl)-3,7-
dimethyl-1-phenylpyrazolo [3,4:2.3]-4H-pyrano |3,2-c| pyran-5-onc 95. 
4-(4-hydroxy-2-oxo-2H-l-benzopyran-2-one-3-yl)-3-mcthyl-l-phcnylpyr 
azolo [3,4;2,3]-4H-pyrano [3,2-b]-l-benzopyran-5-one 96 and 4-(4-
hydroxy-2-oxo-2H-1 -benzopyran-2-one-3-yl)-3-methyl-1 -phenylpyrazolo 
[3,4:2,3]-4H-pyrano [3,2-c]-l-benzopyran-5-one 97. 
Lastly and in continuation of earlier work in the department, 
efforts were directed towards the synthesis of pyranopyridines and 
pyranocoumarins containing 1,3 dicarbonyl unit in the side involving 
translactonization type of rearrangement''^ employing 3-formyl-4-
hydroxycoumarin, 2-amino-3-formylchromone and triacetic acid lactone. 
The reaction when extended to 5-amino-3-melhyl-l-phenylpyrazole-4-
carboxaldehyde did not give the expected product. It instead, gave a 
dimmer 3,6-dimethyl-l,8-diphenyl-diazocino [3,4-c:7,8-c'j bis pyrazole 
106. The dimmer 106 was perhaps obtained through Friedlander 
condensation reaction and is discussed in the thesis. 
The structure of all compounds was established through 
spectroscopic studies. Some of these compounds were evaluated for 
their anti-inllammatory, analgesic, antipyretic and antibacterial 
activities and arc discussed in chapter 4. 

2. Theoretical 
The work on the synthesis of new heterocyclic compounds of 
pharmacological interest has made extensive use of 4-hydroxycoumarin 
derivatives. The presence of OH group at 4-position gives nucleophilic 
character at position 3 to 4-hydroxycoumarin. Another possibility is opening of 
the lactone ring followed by loss of carbon dioxide. During the last thirty years 
synthesis and the study of the biological activities of coumarin derivatives has 
been the aim of many researchers. Also the structure activity relationship of 
coumarins has revealed that the presence of substituents such as methyl, 
formyl, acetyl, and amino groups at position 3 is an essential feature for their 
pharmacological action. Based on the findings, we describe the work done by 
different researcher for the synthesis of compounds featuring different 
heterocyclic rings fused on to the coumarin moiety. Thus, in the context of 
further work on 4-hydroxycoumarin a survey of the literature of thirty years 
was done and some relevant examples are discussed below. 
2.1. The reaction of 4-hydroxycouinarins with benzhydroxymoyi chloride. 
The condensation reaction of 4-hydroxycoumarin la, 8-methyl-4-
hydroxycoumarin lb, and 8-chloro-4-hydroxy coumarin Ic with 
benzhydroxymoyi chloride"^ 4 in the presence of EtsN gives 3-benzoyl-8-
chloro-4-hydroxycoumarin oximes 5a-c. The reaction involves nucleophilic 
attack of double bond at position 3 of 4-hydroxycoumarin on benzonitrile oxide 
generated in situ by base treatment of benzhydroxymoyi chloride (Scheme 1).^  
la-c O H ( B 
C^H 6"5 
5a-c 
a: R = H 
b: R = CH3 
c: R = C1 
Scheme 1. Formation of oximes 5a-c by the reaction of 4-hydroxycoumarins la-c and 
benzhydroxymoyl chloride. 
2.2. The reaction of 4-hydroxycoumarin with 1,4-Naphthoquinone. 
One of the earliest example of 4-hydroxycoumarin 1 with 1,4-
naphthoquinone 6 involves Michael addition of 1 to the 1,4-naphthoquinone, 
oxidation of the resulting quinol 7 by air to give 8 and by more unchanged 1,4-
naphthoquinone, a second Michael addition of 1 and another oxidation of the 
product 9 to give 9a (Scheme 2) / 
Scheme 2. Formation of quinone 9a by the reaction of 4-hydroxycoumarin 1 and 
1,4-naphthoquinone 6, Formation of quinol 9 by the reduction of 
quinone 9a with sodium dithionite. 
The acetylation of 9 forms tetra acetate derivative 10 whereas 
methylation gives unexpected dimethoxycoumestan derivative 11. 
10 
11 
However, when the reaction is extended to 5,5-dimethyicyclohexan-l,3-
dione, the reaction occurs in the same manner except that in the final step, 
cyclization of the disubstituted quinol 12 takes place in preference to oxidation 
(Scheme 3). 
>\^bo^ 
Scheme 3. Formation of 3,3,9,9-tetramethyl-3,4,9,10-tetrahydrobenzo [ 1,2-b:4,5-b'] 
bis (benzofuran-1,7(2H,8H)-dione 13 by the reaction of 1,4-benzoquinone 
and dimedone. 
The reaction of 1,4-benzoquinone with 4-hydroxycoumarin in aqueous 
acetic acid is similar to that reported earlier^ except that the major product is 
colourless quinol 14. Oxidation of 14 with 2,3-dichloro-5,6-dicyano-1,4-
benzoquinone gives the quinone 15 which was identical with that obtained 
from the aqueous acetone reaction. 
14 
An extension to such type of reaction of 4-hydroxycoumarin la-g is 
117 treatment with a-chlorobenzylphenyl ketone 16 in anhydrous potassium 
carbonate to give 4-(l,2-diphenyl-2-oxoethyloxy) coumarins 17a-g which on 
stirring with PPA (P2O5 and H3PO4) undergoes cyclization to furnish the 
cyclized compound 18a-g (Scheme 4).^  
18a-g 
l,18(a-g) : R, R2 R3 R4 
a: H H H H 
b: CH3 H H H 
c: H CH3 H H 
d: H H CH3 H 
e: H H NO2 H 
f: R, = R2 = benzo H H 
g: H H R3 = R4=benzo 
Scheme 4. Formation of coumarins 18a-g by the reaction of 4-hydroxy 
coumarins la-g and a-chlorobenzylphenyl ketone 16. 
In a similar type of reaction 3-(2'-cyclopentenyl)-4-hydroxy [1] benzopyran 
20 is obtained by refluxing 4-hydroxycoumarin 1 and 3-chlorocyclopentene 19 in 
acetone potassium carbonate. Compound 20 is finally converted to its acetate 
derivative 21 by carrying out reaction with Ac20/NaOAc. The acetate 21 was then 
converted to chromone derivative 22 by conducting the reaction with pyridine 
hydrobromide (PyHBrs) in dichloromethane. The same compound 22 is also 
obtained when compound 20 is treated with PyHBrs in CH2CI2. The formation of 
chromone 22 is indicated by Infrared (IR) spectroscopy showing absorption band 
at 1650 cm"' and a double doublet for proton per/ to carbonyl group at 5 8.30 in its 
nuclear magnetic resonance (NMR) spectrum. However, the isomerisation of 
chromone 22 into coumarin 23 takes place when the compound 22 is heated with 
50% of H2SO4 (Scheme 5).^  
^ ^ o 
Acetone / K2CO3 
-HCI 
50% H2SO4 Br 
H 
/ ^ o o^ "o 
Scheme 5. Formation of chromone 22 and coumarin 23 by the reaction of 
4-hydroxycoumarin 1 and 3-chlorocyclopentene 19. 
i n 
2.3. The reaction of 4-hydroxycoumarin with l-aryloxy-4-ehlorobut-2-
ynes. 
Another interesting reaction of 4-hydroxycoumarin is formation of ether 
4-(4-aryloxybut-2-ynyloxy) [1] benzopyran-2-ones 25(a-f). The reaction takes 
place between l-aryloxy-4-chlorobut-2-ynes 24 and 4-hydroxycoumarin 1 in 
refluxing acetone in the presence of anhydrous potassium carbonate 
(Scheme 6).^ 
? ^ . 
MejCO-KjCOj 
^ O A r 
OAr 25a-f 
24 
a, Ar=2-methylphenyl 
b, Ar=4-methylphenyl 
c, Ar=3-methylphenyl 
d, Ar = 2,4-dimethylphenyl 
e, Ar = 3,5-dimethylphenyl 
f, AT = 4-tert-butylphenyl 
Scheme 6. Formation of ether 25a-f by the reaction of 4-hydroxycoumarin 1 
and l-aryloxy-4-chlorobut-2-ynes 24. 
When ether 25a is heated in chlorobenzene, two products are obtained. 
One of the product has been identified as 4-(2-cresoxymethyl) pyrano [3, 2-c] 
[1] benzopyran-5-(2H)-one 26a and the other product as 27. Ether 25b when 
refluxed in chlorobenzene also furnishes two products. One of the product is 
identified as 4-(4-cresoxymethyl) pyrano [3,2-c] [1] benzopyran-5(2H)-one 
26b, and the other product as 28 (Scheme 7). 
11 
OAr 
CfiHcCl / A 
-6"5' 
15h 
25 
OAr 
26a-b 
26a : Ar = 2-methylphenyl 
26b : Ar = 4-methylphenyl 
Scheme 7. Formation of pyranopyran 26a-b by the reaction of ether 25a-b 
and chlorobenzene. 
The fonnation of 27 from 25 may be explained by an initial [3,3] 
sigmatropic rearrangement to give allene moiety 29 followed by isomerisation 
to butadiene 30 by a [1,3] H^ shift"' and acid catalysed cyclisation (enol may 
also act as an acid) of 30 to 27. The product 26 is also formed from 
intermediate 29 via enolisation followed by [1,5] H* shift and electrocyclic ring 
closure. ' Further the compound 27 is formed rapidly in preference to 
product 26a. The product ratio, however, is not changed even when the 
reaction is carried out in purified chlorobenzene or in the presence of toluene 4-
sulfonic acid (Scheme 8). 
12 
? ^ . .OAr 
^ / ^ OAr 
O ^ O 
29 
27 -* 
^ / ^ OAr 
"O O 
i = [3,3] sigmatropic rearangement 
ii = isomerization by 1,3 H® shift 
26(a-f) 
^ - ^ . OAr 
^O O 
Scheme 8. Formation of coumarin 27 and 26(a-f) from ether 25. 
2.4. The reaction of 3-formyl-4-hydroxycoumarin with amines. 
3-Formyl-4-hydroxycoumarin 31a-d is an interesting starting material 
for the synthesis of a variety of heterocycles. One such example is treatment of 
31 with ethanolic solution of hydrazinehydrate, phenylhydrazine and 
hydroxylamine hydrochloride in acetic acid to give corresponding IH, 4H-4-
oxo-benzopyrano [4,3-c] pyrazoles 32a-d, 4H-4-oxo-l-phenylbenzopyrano 
[4,3-c] pyrazoles 32a-h and 4H-4-oxo benzopyran [3,4-c] isoxazoles 33a-d 
(Scheme 9).^  
13 
RNHNH, 
CH3COOH 
EtOH 
O^^O 
32a-h 33a-d 
32a, 33a 
32b, 33b 
32c, 33c 
32d, 33d 
32e 
32f 
32g 
32h 
RI — R2 ~ R3 = H, R — H 
Ri = CH3, R2 — R3 = H, R = H 
R2 ~ CH3 Ri = R3 = H, R = H 
R3 — CH3 R] = R2 = H, R — H 
Ri = R2=R3=H, R = Ph 
R, = CH3,R2=R3=H,R = Ph 
R2=CH3,Ri = R3=H,R = Ph 
R3=CH3,Ri = R2=H,R = Ph 
Scheme 9. Formation of pyrazoles 32a-h and isoxazoles 33a-d by the reaction of 3-
formyl-4-hydroxycoumarin 31 a-d with hydrazines and hydroxylamine 
hydrochloride. 
Another example'" in this category is the reaction of 3-formyl-4-
hydroxycoumarin 31 a-d with malonic acid in the presence of zinc chloride to 
give 2H, 5H-2,5-dioxo-3-pyrano [3,2-c] benzopyranoic acids 34a-d which on 
treatment with methanol in the presence of thionylchloride furnishes methyl 
2H, 5H-2,5-dioxopyrano [3,2-c] benzopyran-3-oates 35a-d. The compounds 
35a-d was further converted into its acid hydrazides 36a-d, upon treatment 
with hydrazine (Scheme 10). 
14 
+ HjC / 
COOH ZnCU 
CHO 
'COOH 
H2NNH2 
C—NHNH2 
36a-d O O 
SOCUin ^ 
MeOH 
COOH 
COOCH3 
35a-d O 
36a : R,,R2, R s ^ H 
36b : Ri = CH3, R2R3 = H 
36c : R,,R3 = H, R2 = CH3. 
36d : Ri,R2 = H, R3 = CH3 
Scheme 10. Formation of hydrazides 36a-d by the reaction of 3-formyl-4-hydroxy 
coumarin 31a-d with malonic acid, thionylchloride and hydrazine. 
K. Rad-Moghadam and M. Moheseni have reported'' the reaction of 3-
formyl-4-hydroxycoumarin 31 with an in situ generated 1:1 adduct of 
triphenyiphosphine and dialkyl acetylenedicarboxylate to form the dialkyl-2H, 
5H-pyrano [3,2-c] [l]benzopyran-5-one-2,3-dicarboxylates (pyranocoumarins), 
38a-c. The reaction may be rationalized on the basis of well-known Chemistry 
of trivalent phosphorus nucleophiles. Addition of triphenyiphosphine to 
acetylenic ester results in a zwitterionic 1:1 adducts which upon abstraction of 
a proton from 31 and concomitant addition of thus formed 3-formylcoumarin-
15 
4-hydroxylate anion produces the key intermediate phosphorane 37. The 
reaction uUimately entails with an intramolecular Wittig reaction of the 
postulated phosphorane 37 (Scheme 11). 
COOR 
CHO HC 
, IK® 
O O COOR 
31 
COOR 
Intramolecular 
Wittig reaction 
COORcoOR 
38a : R = Me 
38b : R = Et 
38c : R = t-Bu PPh, 
38a-c 
Scheme 11. Formation of coumarins 38a-c by the reaction of 3-formyl-4-hydroxy 
coumarin 31 with triphenylphosphine and dialkyl acetylenedicarboxylate. 
2.5. The reaction of 3-formyl-4-hydroxycoumarin with phosphorus 
hydrazides. 
3-Formyl-4-hydroxycoumarin 31 reacts with phosphorus hydrazine 
derivatives NH2-NR2-P(S)(ORi)2 to give phosphorus hydrazide of coumarin 
40a-c/41a-c.''* The same product 40a-c/41a-c is also obtained when chromone-
3-carboxylic ester 39 is treated with phosphorus hydrazines. The reaction 
16 
involved conversion of chromone-3-carboxylic ester to 3-formyl-4-
hydroxycoumarin under basic conditions followed by reaction with phosphorus 
hydrazine to give 40a-c which tautomerized to 41a-c (Scheme 12: Route A). 
However, formyl group of 31 also directly reacts with phosphorus hydrazine to 
give 40a-c which then tautomerizes to 41a-c (Scheme 12: Route B). Both the 
tautomers are present in solution form as well as solid form and are 
inseparable. 
OH /OH 
OCH, 
^ ) O-^ H 
Toutomerization 
O OH O OH 
O ^ ^ O 
41a-c 40a-c 
R=1|J-P(S)(0R,)2 
R2 
3! Rj ~ C2H,5, R2 ~ CH3 
b: R, = CH3 R2 = CHj 
Scheme 12: Route A. Synthetic route to the phosphorus hydrazides of 
coumarin 41a-c and benzopyran-2,4-dione 40a-c. 
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NH,R 
OH /NHR 
41a-c 
R = ]j4-P(S)(OR,)2 
R2 
&'. Rj = C2H5, R2 — CH3 
b:R, =CH3 R2 = CH3 
c: R, = C2H;, R2 = H 
Scheme 12: Route B. Synthetic route to the phosphorus hydrazides of 
coumarin 40a-c and benzopyran-2,4-dione 41a-c. 
2.6. The reaction of 3-acetyl-4-hydroxycouinariii with hydroxylamine. 
3-Acetyl-4-hydroxycoumarin 42 is another interesting starting material for 
the synthesis of heterocyclic compounds of pharmacological value. Thus, in 1955 
Klosa'^ reported that 43 affords crystalline oximes on treatment with excess of 
hydroxylamine hydrochloride and potassium acetate in refluxing ethanol. 
However, Desai and coworkers'^ suggested that the oxime of Klosa was a 
18 
cyclodehydrated product 44. They also said that the oxime 43 is obtained only at 
room temperature and did not undergo Beckmann rearrangement upon treatment 
with SOCI2 or PCI5 and instead gives cyclodehydrated product 44 (Scheme 13). 
Some authors'^ also have reported the formation of isoxazole 44 at room 
temperature under basic conditions. In order to clarify this discrepancy the reaction 
of 3-acetyl-4-hydroxycoumarin 42 with hydroxylamine hydrochloride was 
reinvestigated by Chantegrel et al and found that the reaction of 42 with 
hydroxy lamine under Klosa's reaction conditions affords a mixture of 45 and 46. 
The formation of 45 involves the oxime 43 as intermediate and a nucleophilic 
attack at the C-2 lactone carbonyl by the hydroxyimino group with ring opening 
(Scheme 14). The Compound 46 is obtained by interaction of 45 with an excess of 
hydroxylamine (Scheme 15). 
NHzOH/EtOH 
Room temperature 
Scheme 13. Formation of isoxazole 44 by the reaction of 3-acetyl-4-hydroxycoumarin 
42 and hydroxylamine. 
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Scheme 14. Formation of isoxazole 45 by the reaction of 3-acetyI-4-hydroxycoumarin 
42 and hydroxylamine under the Klosa's reaction conditions. 
\ NH^OH. HCl 
TM *' 
/ (-H2O) ^^^::^oHo^? 
O-H N—Q 
-=Hl 
vVt 
zHl 
+H^  
^---^QH^C^ ^N-OH 
N—Q N— 
0 
46 
-0 
CH3 
Scheme 15. Formation of isoxazole 46 by the reaction of 45 and excess of 
hydroxylamine. 
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2.7. The reaction of 3-acetyI-4-hydroxycoumarm with thiourea and 
arylsulfonamides. 
In another reaction, 3-acetyl-4-hydroxycoumarin 42 is used for the 
synthesis of some antibacterial compounds by carrying out reaction with thiourea 
and benzenesulfonamides 19 
In this context, 3-acetyl-4-hydroxycoumarin 42 is treated with phenyl 
trimethyl ammonium bromide to afford 3-bromoacetyl-4-hydroxycoumarin 47 
which is then treated with thiourea to give 48 in the form of a bromide salt. The 
fmal compound sulfonamide 49a-d is obtained by treating 48 with arenesulfonyl 
chlorides (Scheme 16). 
OH o OH O 
(I) 
42 
^HSOr{Q^^ J 
OH N-
NH,HBr 
49a-d 48 
a : R = CH3 
b : R = C1 
c : R = OCH3 
d : R = NH2 
(I) Phenyl trimethyl ammonium tribromide, THF, 25 °C, 15 min. 
(II) (NH2)2CS, ethanol, reflux 30 min. 
(III) Ar SO2CI, pyridine, 25 °C, 12 hrs. 
Scheme 16. Formation of sulfonamide 49a-d from 3-acetyl-4-hydroxycoumarin 42. 
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2.8. The reaction of 3-acetyl-4-hydroxycoumarin with phenylhydrazine. 
Recently authors have shown the conversion of 3-acetyl-4-
hydroxycoumarin 42 into its hydrazone derivatives by performing the reaction 
under microwave irradiation using Zn [L-proline]2 complex as catalyst^^ in 
order to obtain the high yield of the product as compared to the one obtained 
under the conventional heating procedure. The reaction involved nucleophilic 
addition of hydrazine on acetyl carbon followed by cyclodehydration to form 
the product 50a-c (Scheme 17) 21 
o^ ^o 
MW/120°C 
Zn[L -Proline]2 
R-NHNH2 
-H^ 
RNHNH, 
:^Z 
R" 
,N N^ 
50(a-c) 
50a : R = Ph 
50b : R = ClPh 
50c: R =N02Ph 
Scheme 17. Formation of pyrazoles 50a-c by the reaction of 3-acetyl-4-hydroxy 
coumarin 42 and phenylhydrazines under the microwave irradiation. 
22 

3. Discussion 
3-Acetyl-4-hydroxycoumarin 42 has served as starting material for the 
synthesis of many novel heterocycles. Thus, pyrazole derivatives are obtained 
when the reaction of 3-acetyl-4-hydroxycoumarin is carried out with 
phenylhydrazine. '^ The hydrazone 51 has been earlier shown to undergo 
nucleophilic ring opening followed by cyclodehydration to give 52 on heating 
in acetic acid (Scheme 18) 22 
O CH3 
Scheme 18. Formation of pyrazole 52 by the reaction of 3-acetyl-4-hydroxycoumarin 
42 and phenylhydrazine. 
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It is also shown that on heating the hydrazone 51 with alcoholic HCl, it 
is converted to 53. 
However, when the hydrazone 51 is heated with another mole of 
phenylhydrazine the isomeric compound 54 is obtained (Scheme 19). 
o^ ^o 
HN-NHPh 
N-^NHPh 
Scheme 19. Formation of isomeric pyrazole 54 by the reaction of hydrazone 51 
and phenylhydrazine. 
3.1. Synthesis of chalcones 
These above mentioned reaction involves nucleophilic addition on 
carbonyl carbons of pyrone ring as well as of acetyl group. Thus, it seemed 
interesting to utilize acetyl group of 3-acetyl-4-hydroxycoumarin for the 
synthesis of new heterocycles such as heterochalcones. 
24 
,23 Chalcones are important precursors of flavonoids and are generally 
synthesized from acetophenones and aromatic aldehydes under basic 
conditions.'^ '* Thus, it was thought worthwhile to synthesize new 
heterochalcones employing 3-acetyl-4-hydroxycoumarin 42 and 3-
formylchromone 55, which are heterocycles of pharmaceutical value, under 
very mild basic conditions. The reaction mixture, as expected, afforded 
heterochalcone 56 exclusively as shown in Scheme 20. 
^\(?=^ Pyridine (few drops) 
Scheme 20. Formation of chalcone 56 by the reaction of 3-acetyl-4-hydroxycoumarin 
42 and 3-fonnylchromone 55. 
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The compound 56 gave positive lest with ferric chloride due to phenolic 
4 -OH group. The compound was characterized on the basis of spectroscopic 
data. The IR spectrum (Fig. 1) of 56 showed sharp bands for chromone and 
coumarin carbonyl groups at 1650 and 1734 cm' respeetivel}. fhe broad band 
at 3318 cm"' was due to OH group. Another sharp band at 1610 cm' was 
assigned to carbon-carbon double bond. The 'H N M R spectrum (Fig, 2) of 56 
showed trans olefmic protons Ha and Hb as ortho coupled doublets at 6 9.10 
(J = 15.6 Hz) and 8.18 (J = 15.9 Hz) respectively. The appearance of doublet 
for Ha proton in very low field was due anisotropic effect exerted by two 
carbonyl groups (C-4 and C-1). The presence of chromone moiety was inferred 
through a sharp singlet integrating for one proton (C-2) at 5 8.56 and a doublet 
(J = 7.8 Hz) integrating for one proton (C-5) at 8 8.30. The remaining three 
protons of chromone unit and four protons of coumarin moiety appeared as 
multiplet in the region 8 7.45-7.93. The mass spectrum (Fig. 3) of 56 showed 
M^ at m/z 360 as base peak. The other important peaks were obtained as shown 
in Scheme 21(a-b). 
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OH ^O O 
m/z 360 
56 
OH 90 
O ^ ^ O H ^ , ^ / 0 ^ 
OH O 
0 0 O 
m/z 360 
OH O 
® 
OH O 
H 
f-CH3 
OH O 
m/z 204 
O 
m/z 157 
Scheme 21a. Mass fragmentation of chalcone 56. 
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0 0 O 
m/z 360 56 
RDA 
Cleavage 
m/z 120 
+ • 
+ 
-CO 
c=o 
m/z 92 
m/z 240 
(CH=C=0) 
-X5^ + • 
O O 
m/z 199 
Scheme 21b. Mass fragmentation of chalcone 56. 
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The condensation of a, P-unsaturated carbonyl compounds with 
hydrazines usually results in the formation of pyrazolines.^ "^ Due to presence of 
a, (3 unsaturated carbonyl unit in compound 56 we also thought that reaction of 
56 with hydrazines would occur in usual manner to give 57. 
R = H 
R = Ph 
However, the reaction did not take place as visualized to afford 57. Due 
to the presence of chromone unit in compound 56, the 4-pyrone ring suffered 
ring cleavage ' at C-2 by the nucleophilic hydrazines (hydrazine and 
phenylhydrazine) to form pyrazole moiety along with the formation of 
pyrazoline moiety with a, P-unsaturated carbonyl unit (Scheme 22). 
32 
NH-NH-R 
OH ^NH-NH-R 
R-NH 
^ ^ ^ O H2NNHR '^A 
(-H2O) 
HO / J — N 
^ 58a-b 
58a: R = H 
58b: R = Ph 
Q = 
Scheme 22. Formation of bipyrazoles 58a-b by the reaction of chalcone 56 
and hydrazines. 
The reaction of 56 with hydrazine hydrate afforded 58a and 
phenylhydrazine gave 58b. The ring opening of chromone moiety by 
hydrazines was also confirmed by positive ferric chloride test (thin layer 
chromatography plate developed in chloroform-methanol mixture in the ratio 
3:1 and sprayed with ferric chloride when a black colored spot was observed) 
and absence of diagnostic signal for C-2' proton in the nmr spectra of both the 
compounds. 
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Both the compounds (58a and 58b) were identified on the basis of 
spectroscopic data. The IR spectrum (Fig. 4) of 58a disphiyed broad bands at 
3618, 3456, 3396, and 3269 cm"' due to the presence of two OH and two NM 
groups. A sharp and strong absorption band at 1684 cm' indicated a carbonyl 
group in the compound. Since absorption band for chromone carbonyl groups 
generally appear in the region 1620-1650 cm"',^ ^ the band at 1684 was assigned 
to coumarin rather than chromone carbonyl group. The presence of pyrazoline 
unit in 58a was clearly established by two double doublets at 5 3.66, 3.72 (Ha), 
4.04. 4.09 (Hb) and a multiplet at 6 5.51 (He). The singlet (0 ,0 exchangeable) 
at 8 6.36 was assigned to NH proton of pyrazoline unit. The aromatic region of 
the spectrum showed eight protons of coumarin and phenolic units in the form 
of multiplet at 8 6.91-7.58. A sharp singlet integrating for one proton was 
assigned to Hd proton of pyrazole unit. Two other broad singlets (D2O 
exchangeable) at 5 10.6 and 12.8 were assigned to two OH groups (phenolic 
OH group and 4-OH group of coumarin unit) (Fig. 5). Further confirmation of 
the structure was provided by mass spectrum (Fig. 6) which showed M' at 388. 
The other prominent peaks were obtained as shown in Scheme 23(a-c). 
/ N N 
H m/zl35 
Scheme 23a. Mass fragmentation of bipyrazole 58a. 
35 
HO / N N^ 
H 
m/z 186 
ni/zl59 
Scheme 23b. Mass fragmentation of bipyrazole 58a. 
36 
o^^o. 
H m/z388 
58a 
H m/z295 
m/z387 
H* 
m/z359 
Scheme 23c. Mass fragmentation of bipyrazole 58a 
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When the reaction of heterochalcone 56 was carried out with guanidine 
59 in relluxing AcOIl, the reaction mixture turned reddish brown after 
completion of the reaction, fhe reaction mixture was then poured into cold 
water to afford a dirty white solid. The pure compound, however, was obtained 
as white powder after repeated crystalHzation. 
O NH2 O 
60c' 
As a result of above mentioned reaction the compound 60a or 60b 
should be formed in the normal course of the reaction. The compound, melting 
point 156-158 ''C, showed M' at m/z 377 in its mass spectrum (Fig. 7). 
Therefore, if the nucleophilic guanidine would have reacted with (x. P 
unsaturated unit, 60a should be the possible structure for the compound. If 
pyrone ring of chromonc unit suffers ring cleavage, then structure 60b could be 
assigned to the compound. Hut both the structures were ruled out on the basis 
41 
of M ' . The III spectrum (Fig. 8) showed strong and slightly notched absorption 
bands at 1686 cm' . There was also present a sharp and strong bands at 1620 
cm' . These absorption bands could be easily assigned to a eoumarin, a ketone 
carbonyl and a chromone carbonyl group respectively. In addition to this a 
broad band was also present in the IR spectrum at 3437 cm"' which indicated 
the presence of OH/NH group/s in the compound. The 'll NMR spectrum 
(Fig. 9) of the compound showed presence ofpyrazoline unit due to two double 
doublets each integrating for one proton at 5 3.31 (Ha), 3.63 (Hb) and a 
multiplet also integrating for one proton at 5 4.88 (He). 
The intact chromone ring was inferred by the presence of a sharp singlet 
integrating for one proton at 6 8.45 for C-2 proton. The proton per/ to carbonyl 
group (C-5) was present in the form of double doublets at 8 8.27. There was 
also present a double doublet integrating for one proton at 5 7.99 and may be 
due to C-5 proton of eoumarin unit. Usually four benzenoid protons of 
eoumarin appear as multiplet,^^ but some times splitting of C-5 proton of 
eoumarin moiety also take place.' Rest of three protons of eoumarin and 
chromone units were present as multiplet in the region 6 7.36-7.76. Combining 
these spectroscopic features one arrives at structure 60c/60c' for the compound. 
Probable mechanism for the formation of 60c/60c' is depicted in Scheme 24. 
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H 
56 
.0> H2N-rc—NH2 
59 
HO .NH 
H2N—C 
We 
NH2 
NHn 
60c/60c' 
O NH 
Ac-^0-^C=NH 
t I 
O NH 
® 
OAc H2N 
^ N H 2 
Scheme 24. Formation of 3-amino-l-(4-hydroxy-l-benzopyran-2-one-3-yl]-3-(l-
benzopyran-4-one-3-yl)-propen-l-one 60c/60c' by the reaction of 
chalcone 56 and guanidine hydrochloride. 
Coumarins are also phenolic in nature and therefore give positive test 
with ferric chloride but compound 60c did not give any color when TLC plate 
was sprayed with ferric chloride solution. It may be due to predominant 
existence of compound in the tautomeric form 60c'. The IR spectrum also 
showed only one broad absorption band and that may be givens to NH2 group 
rather than OH group. The structure 60c' was well accorded with M*, which 
was at m/z 377 in its mass spectrum. The other important peaks were obtained 
as shown in Scheme 25. 
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Scheme 25. Mass fragmentation of 60c'. 
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3.2. The reaction of 3-forinyI-4-hydroxycouniarin (31) with active 
methylene compounds. 
3-Formyl-4-hydroxycoumarin 31 is as acidic as acetic acid. The formyl 
group in 31 is labile under strongly acidic or basic conditions. Therefore, the 
condensation reactions of 31 with active methylene compounds such as 4-
hydroxy-6-methyl-2-oxo-2H-pyran-2-one (triacetic acid lactone), 5,5-dimethyl 
cyclohexan-l,3-ciione (dimedone) and 3-methyl-I-phenyl-5-pyrazolone was 
carried out under mild conditions. 
The reaction of 3-formyl-4-hydroxycoumarin (31) and 6,7-dimcthyl-4-
hydroxycoumarin (67) with 4-hydroxy-6-methyl-2-oxo-2H-pyran-2-one 
(Triacetic acid lactone) (64). 
o-Hydroxybenzaldehyde (salicylaldehyde) 61 reacts with 4-hydroxy 
coumarin 1 to give product 62.' In a later study 62 was found to be untenable 
and structure 62 was revised to 63 29 
OTH 
Rearrangement 
48 
In a series of papers, Spanish workers have shown that structures of type 
62 are unstable and consistently rearrange to type 63 through intramolecular 
translactonization.^^ Thus, when salicylaldehyde 61 was treated with triacetic 
acid lactone 64, the intermediate 65 could not be obtained due to its conversion 
to 66 involving translactonization (Scheme 26). 
/ < : > ^ Q H Q J P > \ / C H 3 
o o 
Scheme 26. Formation of 3-acetoacetylcoumarin 66 by the reaction of 
salicylaldehyde 61 and triacetic acid lactone 64. 
Similar type of rearrangement was observed when the reaction was 
extended to 3-formyl-4-hydroxycoumarin 31. Thus, when 31 and 6,7-dimethyl-
3-formyl-4-hydroxycoumarin 67 were treated with triacetic acid lactone 64 in 
alcohol and methanol respectively, the rearranged products 68 and 69 were 
obtained quantitatively (Scheme 27). 
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OTH OH fOii O 
0 - ^ 0 0 ^ 0 ' -CH3 
31:R' = R^=H 
67:R' = R^ = CH3 
R O ^ O O ^ O - -CH3 O^ /CH, 
Intramolecular 
translactonization 
68:R' = R^ = H 
69:R' = R^ = CH3 
Scheme 27. Formation of 3-acetoacetylpyrano [3,2-c] [1] benzopyran-2,5-dione 
68,69 by the reaction of 3-formyl-4-hydroxycoumarins 31,67 and 
triacetic acid lactone 64. 
The structure of compounds 68, 69, obtained as a result of trans 
lactonization, was established on the basis of spectroscopic data. Thus, the IR 
spectrum (Fig. 10) of 69 showed a broad band at 3377 cm"' and a strong and 
sharp band at 1720 cm'' along with another sharp & slightly weak absorption 
band at 1756 cm''. These bands were assigned to OH, coumarin and enol 
lactone carbonyl groups respectively. The ' H N M R (Fig. 11) of 69 exhibited 
50 
the presence of three methyl singlets at 6 2.27. 2.38 and 2.42. Two more 
singlets each integrating for one proton at 6 6.88 and 8.91 were assigned to 
Ha and Hb protons respectively. Two aromatic protons (C-5 and C-8) 
appeared as singlets at 8 7.84 and 7.26. Further confirmation for structure 69 
was provided by mass spectroscopy showing M^  at m/z 326 in its mass 
spectrum (M^+1 peak at m/z 327 in Fig. 12). The other peaks were obtained 
as shown in Scheme 28. 
51 
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( i ) -CH^C \ / \ / ^ ^ I 
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Scheme 28. Mass fragmentation of 8,9-dimethyl-3-acetoacetylpyrano [3,2-c] 
[1] benzopyran-2,5-dione 69. 
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Due to presence of 1,3-dicarbonyl chain, it was thought to obtain 
pyrazoles, isoxazole from 68, 69 and hydrazines, hydroxylamine. Thus, the 
reaction of 68, 69 with hydrazinehydrate, phenylhydrazine, 
hydrazinobenzothiazoie and hydroxyiammonium sulfate afforded pyrazoles 
70a-c, 71a-c and isoxazole 70d (Scheme 29). 
R -^NH-NH-
AcOH/Reflux 
(-H2O) 
CH3 
NH2OH.H2SO4 
HCl/HiO/AcOH 
Reflux 
70d 
68: R ' = R^ = H 
69: R ' = R^ = CH3 
70a:R' = R^  = H,R^ = H 
70b:R' = R^  = H,R^ = Ph 
70c: R R!=H,R^= 
71a:R' = R^  = CH3,R^ = H 
70d:R' = R2 = H 
I _ 
71b: R ' = R^  = CH3, R^  = Ph 
71c:R' = R2 = CH3,R3=(QCg^ 
70a-c, 71a-c 
Thus, the IR speclrum (Fig. 13) of 71a showed a broad band al 3215 
cm"' which can be assigned to NH group. (Wo sharp bands at 1746 and 1721 
cm"' were assigned to enol lactone and coumarin carbonyl groups respectively. 
Two more sharp bands at 1630 and 1559 were assigned to >C=N and >C =C< 
groups respectively. The 'H N M R spectrum (Fig. 14) of 71a exhibited three 
methyl singlets at 5 2.31, 2.38 and 2.40. The aromatic region of the spectrum 
clearly showed four singlets each integrating for one proton at 6 6.71, 7.39. 
7.79 and 8.42. The up field singlet at 6 6.7 was assigned to Ha proton of 
pyrazole moiety. The low field singlet at 5 8.42 was assigned to Hb proton 
(peri to carbonyl group) and two singlets at 7.39 and 7.79 were due to two 
aromatic protons (C-7, C-10). Further confirmation for structure 71a was 
provided by its mass spectrum, which exhibited M^ at m/z 322 (M^+1 peak at 
m/z 323 in the Fig. 15). The peak at m/z 307 was due to loss of methyl group 
from molecular ion peak. The other important peaks were obtained as shown in 
Scheme 30a-b. 
57 
H,C 
O 
m/z 238 
3 2 
m/z 154 (Base peak) 
Scheme 30a. Mass fragmentation of pyrazole 71a. 
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H.C 
N N^ m/z 289 
Scheme 30b. Mass fragmentation of pyrazole 71a. 
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3.3. The reaction of 3-formyI-4-hydroxycoumarin (31) with 5,5-dimethyl 
cycIohcxan-l,3-dione (72) 
Another reaction of 3-formyl-4-hydroxycoumarin 31 which seemed 
interesting, was carried out with active methylene compound, namely. 5.5-
dimethylcyclohexan-l,3-dione (dimedone) 72 in alcohol. The reaction did not 
give 73 as expected from the reaction. Instead, it afforded 74 as a sole product. 
Since formyl group of 3-formyl-4-hydroxycoumarin is very labile under strong 
conditions, it seemed that when the reaction was heated for more than an hr 
deformylation of 3-formyl-4-hydroxycoumarin had taken place to form 4-
hydroxycoumarin which was then added to the double bond of 75 followed by 
removal of OH group from the molecule to form the dimer 74 (Scheme 31). 
63 
C I " H ^ 
iiCk^^^^^xs^O OH 
74 
10^ 
Scheme 31. Formation of 7-(4-Hydroxycouma^in-3-yl)-10,10-dimethyl-8-oxo-
8,9,10,l l-tetrahydropyrano [3,2-c] coumarin 74 by the reaction of 3-
formyl-4-hydroxycoumarin 31 and dimedone 72. 
The formation of high molecular weight dimeric structure 74 was also 
indicated by mass spectroscopy. Thus, mass spectrum (Fig. 16) of the 
compound 74 showed M* at m/z 456. The base peak at m/z 295 was obtained 
64 
as a result of loss of 4-hydroxycoumarin fragment from molecular ion peak 
(Scheme 32). 
Scheme 32. Mass fragmentation of 74. 
65 
Ihe IR spcclrum (Fig. 17) exhibited slightly broad and strong 
absorption band at 1724 cm"' along with another notched peak at 1698 cm" . 
The band at 1724 cm"' indicated presence of more than one coumarin carbonyl 
group in the compound. The other band at 1698 was easily assigned to a ketone 
group. The ' H N M R spectrum (Fig. 18) exhibited two methyl singlets at 5 1.11 
and 1.18. Two more singlets each integrating for two protons at 5 2.36 and 2.38 
were assigned to two methylene (CH2) protons. Another singlet integrating for 
one proton was assigned to methine proton (H-7). Two double doublets each 
integrating for one proton at 6 8.02 (.1 = 7.8 Hz, 1.2 Hz) and 7.92 (.1 = 7.8 Hz, 
1.2 Hz) were assigned to H-1 and H-5' of coumarin units. The remaining six 
aromatic protons were present as a multiple! in the region 5 7.17-7.61. A broad 
singlet (D2O exchangeable) at 5 10.55 was due to OH proton. The presence of 
OH group of coumarin moiety was also confirmed by characteristic ferric 
chloride test. Combining this spectroscopic featuring one arrives at structure 74 
for the compound. 
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3.4. The reaction of 3-formyl-4-hydroxycoumarin (31) with 3-methyl-l-
phenyl-5-pyrazolone (76). 
The reaction of 3-formyl-4-hydroxycoumarin 31 with 3-methyl-l-
phenyl-5-pyrazolone 76 was carried out in the hope of getting 77. The reaction, 
however, did not give the expected product and instead, afforded 78 
(Scheme 33). 
H-,a H,C 
PTS :i Nv^  ^A, Ethanol N^ A O H 
^ N O Reflux ^ N 0-^H " 
Ph 
76 
Ph 
OH o 
H L> H • 
H,C 
I 
Ph 
Q]^ 
I 
Ph 
4HC 
H3C^^ . ^ ^ ^CH, 
I I 
Ph Ph 
I I 
Ph „„ Ph 78 
Scheme 33. Formation of bis pyrazole 78 by the reaction of 3-formyl-4-hydroxy 
coumarin 31 and 3-methyl-l-phenyI-5-pyrazolone 76. 
70 
I he IR spectrum (Fig. 19) olthe compound 78 did not show ain band 
for coumarin carbonyl group. Besides, there was no characteristic signal for 11-
5 proton of coumarin in its 'll NMR spectrum (Fig. 20). It exhibited a singlet 
integrating lor six protons at 6 2.32, which was due to presence of two methyl 
groups in the compound. Another singlet integrating for one proton at 6 7.18 
was assigned to methylene proton. Two multiplets each integrating for two and 
four protons in the region 6 7.24-7.28 and 7.40-7.45 were assigned to 11-4, H-4' 
and 3, 5, 3', 5' protons. Two downfield singlets each integrating for two protons 
at 5 7.88, 7.91, however, were assigned to 2, 6 and 2', 6' protons. It seemed that 
only aldehydic group of 31 reacted with 76 to give dimeric product 78 which 
was supported by its synthesis from 76 and moist triethylorthoformate 
containing a catalytic amount ofp-toluenesulfonic acid (PTS) (Scheme 34). 
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OEt 1 
H—C OEt " HCr=OEt 
•OEt 
® 
OEt 
I 
H — C \ 
-^ EtO 
OEt OEt 
^®0-Et 
I 
H 
H—OEt/ 
XH, H—C. 
I 
Ph 
-EtOH 
HO' ^N 
I 
Ph 
^ N ^ O O - ^ N ^ 
I I 
Ph Ph 
I 
Ph 
H 
H3C. 
Ph 
-CH, H.C. 
^ N OHO ^ N 
r ^ ^ ^ ^ 
'CH. 
2' 6f 
4' 4 
^ N OHO ^ N 
1 1 
Ph Ph 
78 
Scheme 34. Formation of bis pyrazole 78 by the reaction of 3-formyl-4-hydroxy 
coumarin 31 and triethylorthofomiate. 
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3.5. Reaction of 5-chIoro-3-niethyl-l-phenylpyrazole-4-carboxaldehydc (79) 
and 5-azido-3-niethyl-l-phenylpyrazoIe-4-carboxaldehyde (80) with enol 
lactones. 
5-Chloro and 5-azido derivatives have been employed as versatile 
intermediates for the preparation of biologically active compounds.'''^' In the 
heterocyclic area chloroformyl and azidoformylpyrazoles of type 79 and 80 are 
interesting starting materials for two reasons. Firstly CI and N3 groups are easily 
substituted by nucleophiles and secondly the CHO group is ideally suited for 
carrying out functionalization. Since 79 and 80 are easily synthesized in the 
laboratoryZ"*^^ a number of polyheterocyclic compounds are synthesized 
conveniently as shown in Scheme 35"^ and 36.''^  
H,C 
N \ N 
I 
Ph 
79 
r 
I 
Ph 
80 
,R H3C 
Allyl isothiourea / Base^ 
"CI 
,CHO 
'N, 
75 
H,C 
H,C 
R 
81a: CHO, 
81c: C=NMe-0', 
81b:CH = N0H 
81d:CH = N-NHTs 
COzEt 
81e: (2-Phenyltetrazol-5-yi), 81f:C^N.NPh 
81g:CH = NMe-CHC02Et. 81h: CH = NMe-NCOCHjPh 
81i: C=N-0-
Scheme 35. Formation of isoxazoles 82,83 oxathiazocine 84, pyrazole-2-carboxylate 86 
and dipyrazoles 85,87 by the reaction of allylsulfanyl-4-formylpyrazole 
81a-i with NH2OH, CH3NHOH, tosylhydrazide, ethyl iV-methylglycinate 
and A^-methyl-A^-phenylacetylhydrazide. 
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Scheme 36. Formation of pyrimidine 92 from azidoformylpyrazole 80. 
Due to reactive aldehydic group in 79 various fiinctionalization (inter and 
intra molecular) have been carried out using active methylene compovmds 
(Scheme 37).^^ 
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N. 
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93 
COOC2H5 N 
CN H3C 
CONH, 
N CI 
I 
Ph 
CN 
C6H5 
Scheme 37. Formation of pyrazole derivatives from chloroformylpyrazole 79. 
The addition of nitrogen nucleophiles into a, P unsaturated system in 93 
led to the removal of ethylcyanoacetate moiety with the formation of schiffs base 
93a (Scheme 38). 
78 
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H^NR 
HO 93 S) 
— Z—C^r^ / C N 
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COOC2H5 
-(CHfC CN COOC2H5 
NR 
-*- Z—C 
93a 
Z = 5-Chloropyrazol-4-yl 
R = OH,NHPh 
Scheme 38. Formation of schiffs base 93a from 93. 
Further 93 is treated with other nitrogen nucleophiles to give cyclized products as 
shown in Scheme 39 38 
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H,C N^ ^ - ^ N -
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( J /piperidine 
N. 
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I 
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Scheme 39. Reaction of a-cyano-p-(5-chlDro-3-methyl-l-phenylpyrazol-4-yl) 
acrylate 93 with amines and active methylene compounds. 
79 
In the light of above mentioned reactions, the reaction of 79 and 80 was 
carried out with enol lactones such as triacetic acid lactone and 4-hydroxy 
coumarin. The reaction of chloropyrazole carboxaldehyde 79 and azidopyrazole 
carboxaldehyde 80 with triacetic acid lactone 64 afforded 94 and 95 whereas 96 
and 97 were obtained with 4-hydroxycoumarin 1. Perhaps the reactions occurred 
as shown in Scheme 40. 
iN O O ^ CHj 
I 9 8 
Ph 
94 
96 
80 
79: X = CI 
80: X = N3 
64, 94, 95: Z =CH=C-CH3 '? 
1,96,97:Z = 0 Ph 95,97 
N a 
0 C-4 Carbonyl 
is involved in 
Z cyclization 
Scheme 40. Formation of pyrazolopyrones 94,95,96,97 by the reaction of chioro and 
azidoformylpyrazoles 79,80 with 4-hydroxycoumarin 1 and triacetic acid 
lactone 64. 
81 
The isomeric pyranones 94, 95 exhibiting M^ al 418 were distinguished on 
the basis oflR and 'H NMR spectroscopy. Thus, the IR of 94 (Fig. 21) exhibited a 
broad band at 3442 cm"' ibr OH group, a sharp and very strong absorption band at 
1726 cm"' for lactone carbonyl groups and a sharp, slightly less strong band at 
1642 cm"' for chromone carbonyl group. On the other hand the IR spectrum of 95 
(Fig. 22) exhibited slightly broad and strong absorption band for lactone carbonyl 
group at 1703 cm"' in addition to a sharp band 1621 cm" for carbon-carbon double 
bond and a broad band at 3378 cm"' for OH group. The ' H NMR spectrum of 94 
(Fig. 23) showed singlet integrating for six protons at 5 2.05 and another singlet 
integrating for three protons at 5 2.29. These singlets may be assigned to two 
methyl groups of lactone moiety and one methyl group of pyrazole moiety. Two 
more singlets integrating for one and two protons at 5 4.53 and 6.01 were assigned 
to methine protons and C-5 protons of two lactone moieties. The aromatic protons 
of phenyl group attached to nitrogen of pyrazole moiety were present as multiplet 
in the region 5 7.068-7.62 excluding the singlet at 5 7.28 which was due the 
solvent CDCI3. The ' H NMR of 95 (Fig. 24) exhibited the methyl singlet of 
lactone nucleus at 6 2.15 and another methyl singlet at 5 2.31 of pyrazole nucleus. 
Besides these three singlets each integrating for one proton at 5 5.13, 5.93 and 
6.20 were assigned to methine proton and C-5 protons of two lactone moieties. In 
the aromatic region protons of phenyl group of pyrazole moiety were seen as 
multiplet situated in the region 7.26-7.71. A broad singlet (D2O exchangeable) at 
10.12 was due to OH proton. 
82 
The isomeric pyrones 94,96 and 95,97 were probably formed by involving 
intramolecular cyclization involving C-2 carbonyl as well as C-4 carbonyl groups 
of 97a. The formation of isomeric pyranones was justified by drawing analogy 
from the reaction of a phenol 98 with a 3-oxoester 99 to give a coumarin 100, a 
chromone 101 or a mixture of both (Scheme 41) 39 
98 
EtO 
+ 
o=c 
Me 
99 
CH2 
H2S04 
^ ^ o 
O, Me OH V 
/CH2 
P,0 2^5 
EtO—C 
II 
o 
Scheme 41. Formation of coumarin 100, chromone 101 by the reaction of 
phenol 98 and 3-oxoester 99. 
>40 41 The formation of coumarin 100 and chromone 101 involved Simonis 
-42,43 
condensation ' and was further explored to show that product may be one or two 
isomeric benzopyranones.'*'*''*^ Further confirmation for 94 and 95 was done by 
mass spectroscopy as shown in Scheme 42 and 43. 
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Scheme 42. Mass fragmentation of pyrazolopyrone 94. 
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Scheme 43. Mass fragmentation of pyrazolopyrone 95. 
The identification of coumarin products 96 and 97 was again done with the 
help of IR and ' H N M R spectroscopy as both 96 and 97 were having same 
molecular weight, ie. mass spectrum depicted M* for both 96 and 97 at m/z 490. 
Obviously, both benzopyrans were obtained as a resuh of cyclization involving C-
2 and C-4 carbonyl groups as explained earlier. The IR spectra (Fig. 25 and 26) of 
both the compoimds 96 and 97 exhibited broad bands for OH groups at 3451 and 
3078 cm' respectively. The carbonyl region of the spectrum showed a pronounced 
and strongly absorbed band for coumarin carbonyl groups at 1729 cm' of 96 
whereas the compound 97 exhibited two strong absorption bands at 1731 and 
85 
1670 cm''. The former value in 97 was assigned to coumarin carbonyl group and 
the later value to chromone carbonyl group. The ' H N M R spectrum (Fig. 27) of 96 
exhibited a methyl singlet at 5 2.62. The value is. however, slightly high and may 
be due solvent DMSO in which the spectrum was recorded. Another singlet 
integrating for one proton at 5 4.75 was assigned to methine proton. The aromatic 
region exhibited a doublet (J = 7.9 Hz) integrating for two proton and was 
assigned to C-5 proton of two coumarin units. Usually aromatic protons of 4-
hydroxycoumarin appear as muliplet.''^ But we have observed the splitting of C-5 
protons of coumarin unit in a compound associated with another project. The rest 
of eleven protons (six protons of coumarin units + five protons of phenyl group of 
pyrazole moiety) appeared as a multiplet in the region 5 7.25-7.79. The ' H NMR 
spectrum of 97 (Fig. 28) indicated singlet for methyl group at its normal value 
ie. 6 2.12 as the spectrum was recorded in CDCI3. Another singlet integrating for 
one proton at 5 5.36 was assigned to methine proton. Two doublets each 
integrating for one proton at 5 7.97 and 8.04 were assigned to C-5 protons of 
chromone and coumarin units. The remaining eleven protons were present in the 
form of multiplet in the region 5 7.30-7.83. It is' difficult to say which doublet 
corresponds to C-5 protons of chromone or coumarin unit but it appears that the 
value at 8.04 may be assigned to C-5 protons of chromone unit as the value for 
this proton has been reported at 5 8.21.'''' The mass spectrum of compound 96 
exhibited M ' at m/z 490 as base peak (Fig. 29). The appearance of peak at m// 
317 was shown in Scheme 44. 
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Scheme 42. Mass fragmentation of pyrazolopyrone 96. 
The mass spectrum (Fig. 30) of 97 exhibited M^ at m/z 490. The other 
peaks were obtained as shown in Scheme 45. 
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Scheme 42. Mass fragmentation of pyrazolopyrone 97. 
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98 
3.6. The reaction of 5-aniino-3-inethyI-l-phenylpyrazole-4-carboxaldehyde 
(102) with triacetic lactone (64). 
Ahluwalia et. al. synthesized 5-amino-3-methyl-l-phenylpyrazole-4-
carboxaldehyde 102 by reduction of 5-azido-3-methyl-l-phenylpyrazole-4-
carboxaldehyde 80 with H2S in dry methanol.''^  When we tried to synthesize 102 
by above method, no reaction occurred and work up of the reaction mixture gave 
only starting material. A survey of Uterature showed the reduction of azide to 
amine by lithium aluminum hydride'* '^^ ^ or by catalytic reduction.''^ "^^ '^' However, 
F. Rolla has reported the conversion of azide to amine by using sodium 
borohydride in the presence of water in toluene.^ ^ We successfully converted azide 
80 to amine 102 by the method reported by F. Rolla. 
The reaction of 2-amino-3-formylchromone 103 reacts with triacetic acid 
lactone 64 to afford 104. The formation of 104 involved translactonization type of 
rearrangement (Scheme 46). The reaction of amine 102 with triacetic acid lactone 
was attempted to get the expected product 105 through same type of 
rearrangement (Scheme 47) as we had earlier observed it in the formation of 104. 
99 
O T H 
0 \ / N H 2 .NHjO^^O^^CHj 
+ 
103 W6 O 64 
CH3 
Rearrangement 
- H^, + H^ 
Scheme 46. Formation of 3-acetoacetyl-5-oxo-5H-[l]benzopyrano [3,2-e]pyridin-2-one 
104 by the reaction of 2-amino3-fonnylchromone 103 and triacetic acid 
lactone 64. 
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Scheme 47. Formation of 3-acetoacetyl pyrazolopyridone 105 by the reaction of 
aminoformylpyrazole 102 and triacetic acid lactone 64. 
100 
However, the reaction did not proceed as thought. It did not give the 
expected product 105 because the compound did not give the characteristic ferric 
chloride test. The IR (Fig. 31) of the compound did not show any absorption band 
for carbonyl group. It exhibited only bands for C=C groups at 1594 and C=N at 
1550 cm''. The 'H N M R spectrum (Fig. 32) of the compound showed a sharp 
singlet integrating for six protons at 5 2.48. This could be singlet of methyl groups. 
Besides this, there was another singlet integrating for two protons in the down 
field region i.e. at 5 8.19. The aromatic region also depicted multiplets integrating 
for ten protons in the region 5 7.34-7.65. Combining these spectral features one 
arrives at structure 106 for the compound. 
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I 
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XH, 
-N 
N 
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Ph 
The compound 106 was probably obtained as a result of Friedlander 
condensation reaction""^  between two molecules of 5-amino-3-methyl-l-
phenylpyrazole-4-carboxaldehyde 102 (Scheme 48). 
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Scheme 48. Formation of diazocinopyrazole 106 from aminoformylpyrazolel02. 
Further confirmation for 106 was provided by mass spectrum (Fig. 33) 
which showed M^ at m/z 366 ( M ^ l peak at m/z 367) . T h e other important peaks 
were obtained as shown in Scheme 49a-b. 
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Scheme 49a. Mass fragmentation of diazocinopyrazole 106. 
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Scheme 49b. Mass fragmentation of diazocinopyrazole 106. 
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Cfiapter 4 
(yi) Anti-ittflamniatoty, analgesic and 
antipyretic activities 
(<B) JbitiSacteriaC activity 
A. Anti-inflammatory, analgesic and antipyretic activities. 
1. Introduction 
Coumarins, reported to possess multiple biological activities^ are used 
in the treatment of vitiligo, psoriasis and other dermal diseases. The 
physiological properties of natural and synthetic [1] benzopyran-2[H]-ones 
have been reviewed by various workers.^^ In recent times [1] benzopyran-2[H]-
ones have been extensively used as laser materials,''*^ photosensitizers.^' 
brightner, as intermediates for dyes, pesticides and pharmaceuticals as well 
as in perfume formulations^ "*'^ ^ and in enzymology as biological probes.^^ 
Coumarins show activities such as antifungal,^^ anticoagulant,^ *^ antibacterial,^ *^ 
antipyretic,^^ analgesic,^^ and anti-inflammatory.''*'" '^ 
Pyrazole derivatives have been reported to show a broad spectrum of 
biological activities such as antimicrobial,^^ fungicidal,'^ anti-inflammatory7'' 
analgesic,'^ antipyretic,'^ and peptide deformylase inhibitor.'^ Due to 
bioactivity associated with pyrazoles, researchers and chemist are very much 
interested in pyrazole chemistry.''"'^ 
Drugs having anti-inflammatory, analgesic and antipyretic properties are 
one of the most widely used drugs for various medical and surgical conditions 
to the patients. A large number of drugs having the above effects exist with 
potent activity but adverse drug reaction also. So, safe drug is required in order 
to avoid adverse drug reaction. Keeping this in view, the present study has been 
undertaken to investigate the anti-inflammatory, analgesic and antipyretic 
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activities of the synthetic heterocycHc compounds in experimental animal 
models. 
2. Materials and methods 
2.1. Chemicals and test compounds 
Following heterocyclic compounds were tested for anti-inflammatory, 
analgesic and antipyretic activities on animal models in the Department of 
Pharmacology, Jawahar Lai Nehru Medical College, A.M.U Aligarh. 
1. 3-Acetoacetyl pyrano [3,2-c] [1] benzopyran 2,5-dione 68. 
The compound 68 was prepared from intramolecular translactonization of 3-
formyl-4-hydroxycoumarin and triacetic acid lactone. The resulting compound 
68 which possessed a 1,3-diketone unit in its structure were converted to 
pyrazoles by treatment with hydrazine, phenylhydrazine and 
hydrazinobenzothiazole to afford. 
2. 3-(3-Methyl pyrazol-5-yl)-pyrano [3,2-c] [1] benzopyran 2,5-dione 70a 
3. 3-(3- Methyl-1-phenyl pyrazol-5-yl)- pyrano [3,2-c] benzopyran-2,5-
dione 70b 
4. 3-(3-Methyl-l-benzothiazolopyrazol-5-yl)-pyrano [3,2-c] [1] benzo 
pyran-2,5-dione 70c. 
5. 3.6-Dimethyl-l,8-diphenyl-diazocino [3,4-c:7,8-c'] bispyrazole 106 
The compound 106 was obtained from the reaction of 5-amino-3-methyl-l-
phenylpyrazole-4-carboxaldehyde and triacetic acid lactone. 
The test compounds were dissolved in 2.5% DMSO (Dimethyl sulph 
oxide) prior to administration in different concentration so that animal received 
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equal volume each time (5 ml/kg). Dose selection of the test compounds were 
based on preliminary trial carried out in our laboratory over a dose range 5 
mg/kg to 40 mg/kg in geometric increasing order and maximal effect was 
found at the dose of 20 mg/kg. 
Drugs used: 
• Formalin (Merck, India) 
• Diclofenac sodium (Novartis, India) 
• Baker's yeast (Britannia food products, India) 
• Paracetamol (IPCA, India) 
• Pentazocin (Ranbaxy, India) 
2.2. Experimental Animals 
For anti-inflammatory and analgesic activities adult male Wistar Albino 
rats (weight 100-150 gm) and for antipyretic activity young male Wistar 
Albino rats 28-30 days of age (weight 90-100 gm) were used. They were 
obtained from Laboratory Animal Breeding and Research Center Jamia 
Hamdard University, New Delhi. The animals were given a week time to get 
acclimatized with laboratory conditions 
The animals were housed in polypropylene cage (4 per cage) with 
sterilized paper cuttings as bedding material under laboratory conditions with 
control environment of temperature 22 ± 3 °C, humidity (60% ± 10%) and 12 
hrs light/dark cycle. They were given free access to food with standard rodent 
pellet diet (from Lipton, India) and drinking water. The animals were 
transferred to the experimental room 2 hrs before the experiment. All 
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experiments were taken between 10:00 to 16:00 hrs, when the rectal 
temperature reported to be stable.^'' 
The study protocol was approved by the institutional ethical committee. 
2.3. Experimental Protocol 
The following experimental models were used for test compounds. 
a. Anti-inflammatory activity 
a. i. Acute anti-inflammatory model (Paw edema induced by Formalin). 
Method describe by Northover and Subramanian in which 0.05 ml of 
3.5% formalin in normal saline was injected in the subcutaneous tissue of the 
planter surface of right hind paw to produce sub maximal degree of swelling. 
The paw volume was measured at 0, 0.5, 1, 2, 3, 4 and 5 hrs after injection of 
formalin. 
The volume (in milliliters) of the inflamed paw was measured by standard 
volumetric technique, using a calibrated plethysmometer. The paw was 
immersed up to the tibiotarsic articulation (marked with ink) in a cylinder filled 
with mercury. The increased level, consequent on the increase of the mercury 
meniscus, was measured from the increase of dyed ethanol in a glass tube 
connected to the surface of the mercury so that variation of the mercury level 
corresponded to increase in the dyed ethanol in a calibrated glass tube. The 
increase in volume of the paw was calculated by subtracting the initial volume 
from the volume obtained after formalin administration and expressed as paw 
volume increase over time (ml h S.E.M). The effect (percent of negative 
control) for each rat and each group was obtained as follows. 
(Vt - Vo) control ~ (Vt -Vo) treated 
Percentage of inhibition = X 100 
(Vt ~ Vo) control 
(Vo = is average volume of right paw before injection of formalin i.e. at 0 hr 
and Vt = is average volume of right paw after injection of formalin) 
Experimental design and drug treatment: 
Rats were divided into three groups of six rats each. 
Group I: Received 2.5% DMSO 1 hr prior to formalin and served as control. 
Group II: Received test compounds (20 mg/kg, orally) 1 hr before injection of 
formalin. 
Group III: Received Diclofenac sodium (5 mg/kg, orally) 1 hr before injection 
of formalin. 
a. a. Chronic anti-inflammatory activity (Cotton pellets-induced granuloma 
test). 
This method was used, under light ether anesthesia, sterile cotton 
pellets (10 ± 1 mg) were implanted subcutaneously in the groin regions of the 
rats. The test compounds. Diclofenac sodium and control vehicle 2.5% DMSO 
were administered once daily orally for seven consecutive days from the day of 
cotton pellet implantation. The animals were anesthetized on the eighth day and 
cotton pellets were removed surgically and made free from fat and extraneous 
tissues. The wet weights of granuloma were estimated and than pellet were 
dried overnight at 60 "C in hot-air oven to constant weight. The weight of the 
cotton pellet before implantation was subtracted from the weight of the dried, 
dissected pellet. The mean weight was calculated for the pellets from a group 
of rats, and compared with the mean for a group of controls. 
Increment in the dry weight of the pellets was taken as measure of granuloma 
formation. 
The difference in wet and dry weights of granuloma from control group to that 
of treated group indicated the anti-inflammatory activity. 
Experimental design and drug treatment: 
Rats were divided into three groups of six rats each. 
Group I: Received 2.5% DMSO orally daily for seven days and served as 
control. 
Group II: Received test compounds (20 mg/kg) orally daily for seven days. 
Group III: Received Diclofenac sodium (5 mg/kg) orally daily for seven days. 
b. Analgesic activity 
Adult rats weighing 100-150 gm were divided into three groups (n = 6) 
and analgesic activity was tested by (i) Hot-plate method (ii) Formalin test. 
Group I: Received 2.5% DMSO orally 30 min before experiment. 
Group II: Test compound 20 mg/kg were administered orally 30 min before 
experiment. 
Group III: Pentazocin (15 mg/kg) was given intraperitoneal 15 min prior to 
experiment. 
f^gSlS 
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Experimental design and drug treatment: 
b. i. Hot-plate method 
The method was described by Eddy and Leimbach. Rats were 
screened by placing them on the hot plate (Eddy's hot plate from Techno India) 
maintained at 55 ± 1 °C and reaction time in seconds for hind paw licking or 
jumping was recorded. Only rats, which reacted within 5 to 10 seconds, were 
used in the study. Those animals in which the reaction time is increased to at 
least twice the mean reaction time for control animals or control reading plus 
eleven seconds (control+11 seconds) were taken as showing significant 
analgesia. Pentazocin was used as standard drug. 
b. a. Formalin test 
Thirty minutes after administration of the test compounds or Diclofenac 
sodium and 15 minutes after Pentazocin intraperitonealy, 20 ^1 of 2.5% 
formalin in saline was injected subcutaneously to a hind paw of the rat. The rat 
was observed for 30 min after the injection of formalin, and the amount of time 
spent licking the injected hind paw was recorded and the data were expressed 
as total licking time in the early phase (0-5 min) and the late phase (15-30 min) 
after formalin injection. The early phase represents neurogenic pain while the 
latter phase is of inflammatory pain. 
c. Antipyretic activity 
c.i. Baker's yeast induced pyrexia. 
I'cvcr was induced by intraperitoneal injection of baker's yeast 135 
mg/kg, which induced a sustained increase in rectal temperature for 5 hrs. 
Paracetamol and other novel antipyretics, reverted baker's yeast-induced 
fever."' The test compounds and Paracetamol (standard drug) were 
administered 1 hr after injecting yeast when there was an average increase in 
temperature of about 1 °C. 
Rats were divided into four groups (n = 6). The animals were set in 
their cages individually throughout the experiment. Rectal temperature was 
measured with a lubricated thermister probe inserted 3 cm deep into the 
rectum. The probe was linked to telethermometer (range 31-41 "C with O.l °C 
precision) for 5 hrs, Rectal temperature was measured every 15 min for each 5 
hrs and recorded manually at specified intervals. 
To minimize the stress response of the animals to the lightly restrained 
condition, we made a careful handling and performed two sets of acclimatizing 
training in the cage for 2 days before starting the experiments. 
Experimental design and drug treatment: 
Group 1: (Control) only yeast was injected and continuously temperature 
was monitored and recorded at specified interval for 5 hrs. 
Group II: Received 2.5% DMSO orally 1 hr after administering yeast. 
Group III: Test compounds (20 mg/kg) was administered orally 1 hr after 
administering yeast. 
Group IV: Paracetamol (150 mg/kg) was given orally 1 hr after administering 
yeast. 
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c. /'/. Basal rectal temperature. 
Test compounds and Paracetamol were given orally and rectal 
temperature was measured every 15 min for each 5 hrs and recorded manually 
at specified intervals. 
Group I: Received 2.5% DMSO given orally. 
Group II: Test compounds (20 mg/kg) was administered orally. 
Group III: Paracetamol (150 mg/kg) was given orally. 
d. Toxicity study 
The acute oral toxicity was carried out as per the guidelines set by the 
organization for the economic co-operation and development (OECD) received 
from the committee for the purpose of control and supervision of experimental 
animals (CPCSEA). 
Experimental design and drug treatment: 
or 
In toxicity study two rats (one from either sex) were dosed at 
predetermined [250, 500 and 1000 mg/kg dissolved in fixed amount (1.5 ml) of 
DMSO] and administered by stomach feeding cannula. They were observed 
continuously for the first 2 hrs for toxic symptoms and up to 24 hrs for 
mortality. If there was no mortality or if no more than one rat of either sex 
died at the highest level tested (1000 mg/kg) with the total of 10 rats (5/sex) 
dosed at 1000 mg/kg and monitored for 7 days period LD50 was considered to 
more than 1000 mg/kg. 
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Statistical analysis 
Experimental data were expressed as mean ± S.E.M. Student's t-test was 
applied for expressing the significance and P value <0.05 was considered as 
significant. 
3. Results 
a.i. Acute inflammation model (formalin induced paw edema) 
The results of the anti-inflammatory effect of the test compounds on formalin 
induced edema in rat's right hind paws were presented in Table 1& 2. There 
was a gradual increase in edema paw volume of rats in the control (Formalin 
treated). However, in the test groups, the compounds showed a significant 
reduction in the edema paw volume. As indicated in Table 2. the significant 
anti-inflammatory effect induced by test compounds 70a, 70b, 70c and 106 
appeared at 1-2 hrs and progressively increased and reached a maximum 46.15, 
88.46, 65.38, 78.84% respecfively at 5 hrs, while the maximum anti-
inflammatory effect of test compound 68 appeared at 1 hr (60%). The anti-
inflammatory effect induced by Diclofenac sodium progressively increased and 
reached a maximum (70.83%) at 2 hrs. It was maintained up to 5 hrs. The anti-
inflammatory effect of 70b was more potent as compared to others. 
a. a. Cotton pellet induced granuloma (Chronic model) 
In the chronic model (cotton pellet induced granuloma) the Icsl 
compounds and Diclofenac sodium significantly reduced both wet as vvcll as 
dry weights in cotton pellet granuloma (Table 3). I'he efiect of test compound 
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70b in botli reducing wet weight and dry weight of cotton pellet induced 
granuloma was similar to that of Diclofenac sodium. 
b. i. Hot plate reaction time in Rats 
The results of hot-plate test indicated a significant increase in reaction 
time at 2 hrs (2.5 fold), 3 hrs (3.0 fold) and 4 hrs maximum effect up to cut-off 
time) with the test compounds, whereas reference drug Pentazocin, a centrally 
acting analgesic drug, markedly increased pain latency at 1 hrs (2.5 fold) and 
achieving maximum effect (up to cut-off time) at 2 and 3 hrs (Table 4). 
b. a. Formalin test 
As shown in Table 5 the pretreatment with test compounds caused a 
significant inhibition of the neurogenic (early phase) and inflammatory phases 
(late phase) of formalin induced licking in rats. 
The standard drug, Diclofenac sodium (5 mg/kg) also significantly 
inhibited formalin induced licking in rats but only in late phase (15-30 minute) 
In contrast, the reference antinociceptive drug Pentazocin (15 mg/kg) 
significantly reduced the licking activity against both phases of formalin-
induced nociception. 
c.i. Effect of test compounds and Paracetamol on Yeast-induced pyrexia 
The experimental rats showed a mean increase of about 1 °C in rectal 
temperature 1 hr after backer's yeast injection (135 mg/kg, i.p). The test 
compounds (68, 70a, 70b, 70c and 106) produced significant (P<Q.05) 
antipyretic activity at 2 and 3 hrs. Among these test compounds, 70b and the 
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reference drug Paracetamol (150 mg/kg) showed significant antipyretic activity 
throughout the observation period up to 5 hrs (Fig 34). 
c. a. Effect of test compounds and Paracetamol on basal rectal temperature. 
The result showed by the test compounds and paracetamol on normal 
body temperature in rats was presented in Fig. 35. The test compounds 68 and 
70c were lowering of body temperature at 2 hrs (0.12 and 0.5 °C respectively) 
following its administration. While the maximum lowering of the rectal 
temperature noticed with the test compounds 70b and 106 were 0.2 and 0.25 °C 
respectively at 1 hr and that of compound 70a standard drug Paracetamol were 
0.1 and 0.05 °C at 1 and 3 hrs respectively. 
d. Acute toxicity study evaluation 
In acute toxicity study the test compounds did not show any toxicity and 
mortality up to maximum dose of 1000 mg/kg body weight in rats. No gross 
change in behavior was observed at this dose. Weight of rats had a normal 
variation after 7 days of observations. 
4. Discussion 
Various coumarin and pyrazole-related derivatives were recognized as 
inhibitors of lipoxygenase and cycloxygenase pathways of arachidonate 
metabolism and also of nculrophile-dependcnl super oxide anion generation."'^  
Several natural or synthetic coumarins and pyra/oles with various hydroxy! and 
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other substituents were found to inhibit lipid peroxidation, to scavenge 
hydroxyl radicals and superoxide anion^" and lo influence processes involving 
free radical-mediated injury, as can some plant phenolics and flavonoids. 
The results of this study indicate the synthetic new heterocyclic 
derivatives of coumarin and then conversion to pyrazoles by addition of 
different groups possess acute and chronic anti-inflammatory, antipyretic and 
analgesic activities on animal's models. 
It is well known that inhibition of edema induced by formalin in rats is one 
of the most suitable test procedures to screen antiarthritic and antiinflammatory 
agents, as it closely resembles human arthritis.^' Arthritis induced by formalin 
is a model used for the evaluation of an agent with probable antiproliferative 
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activity. 
The formalin-induced inflammation in the rats foot may be conveniently 
divided into two parts, the first involving 5-hydroxytryptamine as mediator and 
the second some mediator which is unrelated to 5-hydroxytryptamine. The 
portion of the total response, which is due to the release of 5-
hydroxytryptamine, can be prevented by either depleting the skin of 5-
hydroxytryptamine or by giving the rats an antagonist of 5-hydroxytryptamine. 
It also seems probable that the portion of the total response which is due to the 
second mediator" can be prevented by treatment with certain analgesic-
antipyretic drugs (acetylsalicylic acid) and other substances like the 
hydroxybenzoates. the pyrazolones, the flavone and flavanone glycosides are 
inactive against 5-hydroxytryptamine-induccd inflammation but they produce 
Iheir action against a formalin-induced inflammation by inactivating the second 
factor.'^ ' Another possibility is that an anti-inflammatory agent might operate 
by releasing or activating some endogenous factor, which is anti-inflammatory. 
It is well known that the salicylates, for example, release both adrenal cortical 
and adrenal medullary hormones*^^  and although the adrenal cortical hormones 
are inactive against formalin-induced inflammation in the rats foot, the adrenal 
medullary are active.^ "'^ ^ 
The test compound 68 exhibited significant anti-inflammatory 
activity with maximum effect at 3 hrs. However, the compounds 70b and 106 
exhibited markedly improved anti-inflammatory activity and was as good as 
Diclofenac sodium. The compounds 70a and 70c also exhibited significant 
anti-inflammatory activity but to a lesser extent. 
As the test compounds significantly inhibited this model of inflammation, 
it can be thought to possess antiproliferative and antiarthritic activities similar 
to Diclofenac and salicylates, the cyclooxygenase inhibitors. 
The cotton pellet method is widely used to evaluate the transudative and 
proliferative components of the chronic inflammation. Inflammation and 
granuloma develops during the period of several days. The Inflammation 
involves proliferation of macrophages, neutrophils and fibroblasts, which are 
basic sources of granuloma formation. The wet weight of the cotton pellets 
correlates with the transuda; the dry weight of the pellets correlates with the 
amount of the granulomatous tissue."^ '^'^  Hence, the decrease in the weight of 
granuloma indicates the ability of the test compounds in reducing the synthesis 
120 
of proteins, collagen and infiltration of macrophages. Administration of test 
compounds (20 mg/kg) and Diclofenac sodium (5 mg/kg) appear to be 
effective in inhibiting both the wet weight and dry weight of cotton pellet 
(Table 3). The test compounds 70b and 106 (20 mg/kg) appear to be equally 
effective to that of Diclofenac sodium (5 mg/kg) in inhibiting both the wet 
weight and the dry weight of cotton pellets. 
Thermic painful stimuli (hot-plate test) are known to be selective to 
ng 
centrally, but not peripherally, acting analgesic drugs. The test compounds 
produced a significant inhibitory effect on the nociceptive response at 2, 3 and 
4 hrs though less potent than that of the Pentazocin, a centrally acting analgesic 
drug, which significantly increased the reaction time in hot-plate test at 1,2, 3, 
and 4 hrs. 
The formalin test is another pain model, which assesses the way an 
animal responds to moderate, continuous pain generated by injured tissue.'^ '' 
Centrally acting drugs such as morphine inhibited both of the early and late 
phases equally while peripherally acting drugs such as Aspirin only inhibited 
the second phase.'"""" 
In the present study the test compounds significantly inhibited both the 
neurogenic pain (early phase) and inflammatory phase (later phase) except 70a 
that has no significant role in inhibiting neurogenic pain. Pentazocin 
significantly reduced the licking activity in both phases while Diclofenac 
decreased the licking activity only in the late phase. 
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one of the possible mechanisms that contribute to the central antinociceptive, as 
well as antipyretic activities of the test compounds seen in the present study. 
The involvement of the opioid system in the antinociceptive activity could also 
be suggested, based on the claim by Chan et al.'°^ and Hosseinzadeh and 
Younesi'^* that centrally acting drugs like opioids affect both phases of the 
formalin and hot plate tests, respectively. 
Based on the results it can be concluded that the new heterocyclic 
derivatives possess significant role in inhibition of both acute and chronic 
phases of inflammation. 
Additions of different functional groups have varying effects. 
Significant increase in anti-inflammatory effect of compound 68 was observed 
after addition of phenylhydrazine. The synthetic new coumarin and pyrazole-
related derivatives have potent analgesic and antipyretic activity. 
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Table 2: Percentage Inhibition in formalin induced paw edema by test compounds 
68, 70a, 70b, 70c, 106 and Diclofenac sodium. 
Test % Inhibition 
Compounds Dose/kg 0.5 hr 1 hr 2 hr 3 hr 4 hr 5 hr 
DMSO 5ml . . . . . . 
68 20 mg/ 40 60 45.83 38.70 22.22 25 
0.067 mmole 
70a 20 mg/ 00 40 41.66 38.70 38.88 46.15 
0.068 mmole 
70b 20 mg/ 40 53.33 62.50 70.96 77.77 88.46 
0.054 mmole 
70c 20 mg/ 00 46.66 58.33 45.16 50 65.38 
0.046 mmole 
106 20 mg/ 40 60 62.50 67.74 75 78.84 
0.054 mmole 
Diclofenac 5 mg/ 40 66.66 70.83 67.74 66.66 65.38 
Sodium 0.017 mmole 
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Table 3: Effects of test compounds 68, 70a, 70b, 70c, 106 and Diclofenac sodium on 
cotton pellet induced granuloma. 
Weight of cotton pellets 
Test 
Compounds Dose/kg Wet weight % inhibition Dry weight % inhibition 
DMSO 5ml 183.7±11.5 79.3 ±3.5 
68 20 mg/ 100 ±9.5* 
0.067 mmole 
45.56 39.6 ±2.6* 50.06 
70a 20 mg/ 99.5 ± 8.2* 
0.068 mmole 
45.83 42.0 ±2.3* 47.03 
70b 20 mg/ 79.0 ±4.5* 
0.054 mmole 
56.99 30.35 ±1.6* 61.72 
70c 20 mg/ 115.0 ±10.2* 37.39 
0.046 mmole 
44.0 ±2.9* 44.51 
106 20 mg/ 81.5 ±4.0* 
0.054 mmole 
55.63 30.4 ±2.1* 61.66 
Diclofenac 5 mg/ 84.5 ± 6.3* 
Sodium 0.017 mmole 
54.00 30.0 ±1.8* 
The results given are mean ± S.E.M; number of animals used (n = 6). 
*P value of < 0.05 was considered as significant in comparison to control. 
62.17 
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Table 5: Anti-nociceptive activity of test compounds 68, 70a, 70b, 70c, 106, 
Pentazocin and Diclofenac sodium on formalin induced pain. 
Test Total time spent in Paw licking time (s) 
compounds Dose/ kg 
Phase (0-5) % inhibition Phase (15-60) % inhibition 
DMSO 5ml 62.2 ±5.2 - 146.4±12.3 
68 20 mg/ 40.1 ±2.2* 35.53 88.3 ± 7.0* 39.68 
0.067 mmole 
70a 20 mg/ 46.2 ±1.4 25.72 96.2 ±4.4* 34.28 
0.068 mmole 
70b 20 mg/ 34.3 ±2.0* 44.85 52.4 ±6.2* 64.20 
0.054 mmole 
70c 20 mg/ 38.7 ±6.3* 37.78 96.2 ±8.4* 34.28 
0.046 mmole 
106 20 mg/ 35.2 ±2.0* 43.40 56.5 ± 6.2* 61.36 
0.054 mmole 
Pentazocin 15 mg/ 18.2 ±3.2* 70.79 40.6 ±8.7* 72.26 
0.052 mmole 
Diclofenac 5 mg/ 54.3 ±2.4 12.70 64.2 ±5.3* 56.14 
Sodium 0.017 mmole 
The results are mean ± S.E.M from 6 animals *P<0.05, when compared to vehicle control 
(DMSO). 
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B. Antibacterial activity 
Introduction 
Infectious diseases continue to be one of the most dreaded diseases 
leading to a large number of premature deaths in the entire world. The 
enhancement of multiple drug resistant bacteria threatens the world's 
population. Hence, in the present scenario of antibiotic therapy, there is a 
continuing quest of new antimicrobial' drugs. 
In this chapter we have discussed antibacterial activity of compounds 
68, 69, 70a, 70b, 70c, 70d, 71a, 71b, 71c, 74, 78 and 106 synthesized in our 
laboratory. 
1. Materials and Method 
(i^  Microorganisms Used: 
The test organisms used included Escherichia coli ATCC 25922, 
Staphylococcus aureus ATCC 25923, Pseudomonas aeruginosa ATCC 27853, 
Streptococcus pneumoniae. Shigella dysenteriae. Salmonella typhi and 
Klebsiella pneumoniae. 
(ii) Culture Media and Inoculum : 
The microbial cultures were diluted in nutrient broth to obtain a cell 
suspension of 10^  CFU/ml. 
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(iii) Antimicrobial assays: 
The Disc diffusion method'"'^  with little modification was used to 
determine the antibacterial activity of some compounds. Briell}' 0.1 ml of 
diluted inoculum (10' CFU/ml) of test bacteria was spread on nutrient agar 
plates. Sterile paper disc impregnated with 70 |j,g of compound in DMSO and a 
disc without compound was used as a negative control. The plates were 
incubated for 18 hrs at 37 °C for test bacteria. The antibacterial activity was 
evaluated by measuring the zone of inhibition around the disc of tested 
compound. Antibiotic Chloramphenicol (30^g/disc) was used as positive 
control. 
Except 71a, 71b which didn't show any antibacterial activity. All 
compounds exhibited antibacterial activity towards various gram positive and 
gram negative bacteria. Interestingly the compound 68 showed moderate 
activity against gram positive bacteria Staphylococcus aureus and compound 
70c showed antibacterial activity (zone diameter 18 mm) against gram negative 
bacteria Pseudomonas aeruginosa for which the antibacterial drug 
Chloramphenicol did not show any activity. All other compounds showed 
pronounced to moderate broad spectrum antibacterial activity (both gram 
positive and gram negative bacteria). Thus, it was clearly observed from Tabic 
6 and 7 that the compounds 70a, 70b showed good activity against gram 
positive bacteria. Staphylococcus aureus and no activity against Streptococcus 
pneumoniae. Interestingly, both the compounds exhibited some activity against 
gram negative bacteria, Pseudomonas aeruginosa (zone diameter 11 and 21 
[31 
mm respectively) for which the antibacterial drug Chloramphenicol didn't show 
activity. The compound 70a also showed good activity against gram negative 
bacteria Shigella dysenteriae and klebsiella pneumoniae whereas compound 
70b showed pronounced activity against gram negative bacteria, Escherichia 
coli, Salmonella typhi and Klebsiella pneumoniae as compared to 
Chloramphenicol. Further compounds 69 and 71c exhibited moderate activity 
against gram negative bacteria, Escherichia coli. Shigella dysenteriae and no 
activity against Pseudomonas aeruginosa, Salmonella typhi, Klebsiella 
pneumoniae as compared to antibacterial drug Chloramphenicol. 
The compounds 70d, 74 and 78 were not active against both gram positive 
bacteria {Staphylococcus aureus and Streptococcus pneumoniae) and gram 
negative bacteria Klebsiella pneumoniae. However, compound 70d showed 
moderate activity against Salmonella typhi and Shigella dysenteriae and no 
activity against Escherichia coli and Pseudomonas aeruginosa. The compound 
74 again did not show any activity against Salmonella typhi. Both 74 and 78 
were moderate active against Escherichia coli and Shigella dysenteriae. Further 
74 did not show any activity Salmonella typhi whereas 78 was not active 
against Pseudomonas aeruginosa. Among all these compounds the most potent 
compound was 106 which showed maximum activity against both gram 
positive as well as gram negative bacteria (comparable to Chloramphenicol). 
However the compound was not active against two bacteria only viz. 
Streptococcus pneumoniae (gram positive) and Shigella dysenteriae (gram 
negative). 
132 
Table 6: Antibacterial activity of compounds 68, 69, 70a, 70b, and 70c. 
Organism Test organisms Inhibition zone size in mm 
68 69 70a 
(70^g (70^g (70^g 
/disc) /disc) /disc) 
70b 70c 
(70^g (70^g 
/disc) /disc) 
Antibiotic 
control* 
Gram +ve Staphylococcus 9.0 
Bacteria aureus 
12 18 22 
Streptococcus 
pneumoniae 
21 
Gram -ve 
Bacteria 
Escherichia coli 
Pseudomonas 
aeruginosa 
10 
11 
22 
21 18 
23 
Salmonella 
typhi 
19 16 
Shigella 
dysenteriae 
10 12 23 
Klebsiella 
pneumoniae 
13 21 23 
•Antibiotic control: Chloramphenicol (30|ig/disc). 
- No activity detected. 
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Table 7: Antibacterial activity of test compounds 70d, 71c, 74, 78 and 106. 
Organism 
Gram +ve 
Bacteria 
Gram -ve 
Bacteria 
Test organisms 
Staphylococcus 
aureus 
Streptococcus 
pneumoniae 
Escherichia coli 
Pseudomonas 
aeruginosa 
Salmonella 
typhi 
Shigella 
dysenteriae 
Klebsiella 
pneumoniae 
70d 
(70 i^g 
/disc) 
_ 
-
-
7.0 
10 
-
Inhibition zone size in mm 
71c 74 78 
(70^g (70ng (70^g 
/disc) /disc) /disc) 
_ _ _ 
-
11 8.0 10 
7.0 
8.0 
8.0 8.0 8.0 
-
106 
(70^g 
/disc) 
22 
-
22 
15 
18 
-
25 
Antibiotic 
control* 
22 
21 
23 
16 
23 
23 
* Antibiotic control: Chloramphenicol (SO^g/disc). 
No activity detected. 
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Experimental 
General 
The melting points were taken in open capillaries and are 
uncorrected. The Infrared spectra were recorded on Interspec 2020 
spectrometer using KBr. Ultra-voilet spectra in 95% methanol, DMSO 
were measured on USB 2000 Ocean-Optical spectrophotometer and 
wave lengths, X a^x were expressed in nm. The 300 MHz ' H N M R and 
high resolution FAB mass spectra were provided by Sophisticated 
Analytical Instrument Facility (SAIF), CDRI, Lucknow. The ' H NMR 
spectra were recorded using DMSO and deuterated chloroform as the 
solvent, in which the chemical shifts were reported in 5 values relative 
to TMS as internal standard. m-Nitrobenzyl alcohol was used as the 
matrix for recording the FAB mass spectra. Peaks at m/z 136, 137, 
154, 289, 307 which appear in mass spectrum were due to matrix. 
G.C.M.S were recorded on a Thermofinnigan LCQ Advantage max ion 
trap mass spectrometer. The purity of the compounds was checked by 
TLC on glass plates coated with silica Gel G (Merck Germany) using 
benzene - ethyl acetate (4:1), chloroform-methanol (9:1) as mobile 
phase and visualized by iodine vapour and alcoholic ferric chloride. 
All the solvents and chemicals used were AR grade. 4-
Hydroxycoumarin, dehydroacetic acid, triethylorthoformate, 3-methyl-l-
phenyl-5-pyrazolone, acetophenone, benzaldehyde, N,N-dimethyl 
^1': 
formamide, Guanidine hydrochloride and phosphorous oxychloride 
were obtained from E. Merck (Germany). Dimedone and 
hydroxylammonium sulfate were obtained from CDH (India). 
3-Formyl-4-hydroxycoumarin,"'^ 3-acetyl-4-hydroxycoumarin, 
3-formylchromone,"^ triacetic acid lactone,"^ hydrazinobenzothiazole, 
5-chloro-3-methyl-1 -phenyl-pyrazole-4-carboxaldehyde,^'' 5-azido-4-
formyl-3-methyl-l-phenyl pyrazole were synthesized by reported 
method. 
The reaction of 3-acetyl-4-hydroxycouinarin (42) with 3-formyIchroinone 
(55). 
Formation of (2E)-l-(4-hydroxy-l-benzopyran-2-one-3-yl)-3-[l] (benzo 
pyran-4-one-3-yl)-2-propen-l-one (56). 
To a well stirred solution of 3-acetyl-4-hydroxycoumarin 42 (1.0 
gm, 4.9 mmole) in ethanol (30 ml) containing pyridine (0.5 ml) was 
added 3-formylchromone 55 (0.85 gm, 4.9 mmole). The reaction mixture 
was refluxed on water bath for 12 hrs, cooled at room temperature and 
poured into ice-cold water (200 ml). The light yellow solid (2E)-l-(4-
hydroxy-1 -benzopyran-2-one-3-yl)-3-[ 1 ] (benzopyran-4-one-3-yl)-2-propen-1 -
one 56, as obtained, was filtered, washed with water, alcohol, dried and 
recrystallized from chloroform as shining needles; yield 65%; m.p.260-
262 "C. 
Spectral Data: 
UV (MeOH) X max : 210.07, 270.29, 307.09, 347.24 nm. 
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IR (KBr) v„ax 3318, 1734, 1650 and 1610 cm" 
' H N M R ( 3 0 0 M H Z , CDCI3) 5 7.45-7.93 (m, 7H, Ar-H), 8.18 
(d, IH, J=15.9 Hz, Hb), 8.30 (d, 
IH, J=7.8 Hz, H-5' ), 8.56 (s, IH, 
H-2'), 9.10 (d, IH, J=15.6 Hz, Ha). 
MS (% rel. Int.) 
Analyzed for C21 H12 06 
m/z 361 (M*+l, 100), 342 (30), 
240 (5), 204 (90), 199 (35), 171 
(20), 156 (20), 120 (40), 107 (15), 
92(10). 
Calculated C - 70, H = 3.33%; 
Found C = 7.25, H = 3.53%. 
The Reaction of (2E)-l-(4-hydroxy-l-benzopyran-2-one-3-yl)-3-[l] 
(benzopyran-4-one-3-yl)-2-propen-l-one (56) with hydrazine 
hydrate. 
Formation of 3-[4-hydroxy-[l] benzopyran-2-one-3-yl]-5-[5-(2-
hydroxyphenylpyrazoI-4-yI]-pyrazolin (58a). 
(2E)-1 -(4-hydroxy- l-benzopyran-2-one-3-yl)-3-[ 1 ] (benzopyran-
4-one-3-yl)-2-propen-l-one 56 (1.0 gm, 2.7 mmole) was dissolved in 
alcohol (25 ml) and hydrazine hydrate (1.6 ml, 5.4 mmole) added to it. 
The reaction mixture was refluxed on water bath for 30 min. On cooling 
at room temperature, a light green solid 3-[4-hydroxy-[l] benzopyran-2-
I I T 
one-3-yl]-5-[5-(2-hydroxyphenylpyrazol-4-yl]-pyrazolin 58a was 
obtained. It was filtered, washed with ethanol-water, dried and 
recrystallized from DMF; yield 79%; m.p.l62 "C. 
Spectral Data: 
UV (MeOH) I n,a,x 206.72, 248.54, 343.89, 348.91, 
439.24 nm. 
IR (KBr) V 
max 
3618, 3456, 3396, 3269, 1684, 
1608 and 1578 cm 1 
' H N M R (300 MHz, DMSO-dfi) 5 3.72 (dd, IH, J - 17.7 Hz, 8.1 
Hz, Hb), 4.09 (dd, IH, J = 17.1 
Hz, 8.7 Hz, Ha), 5.15 (m, IH, He), 
6.37 (br s, IH, exchangeable, 
NH), 7.81 (s, IH, Hd), 6.91-7.58 
(m, 8H, Ar-H), 10.60 (br s, IH, 
exchangeable, OH), 12.80 (br s, 
IH, exchangeable, OH). 
M S (% rel int) m/z 389 (M^+1, 100), 388 (50), 387 
(40), 386(70), 370(15), 342(5), 
295 (7), 268 (8), 240 (40), 229 
(50), 227(10), 161 (20), 159(5), 
134(25), 136(25), 118 (20), 107 
(10). 
Analyzed for C2I H,6 N4 04 Calculated C = 64.94, H = 4.12, 
N = 14.43%; Found C - 65.14, 
H = 4.35,N = 14.63%. 
The reaction of (2E)-l-(4-hydroxy-l-benzopyran-2-one-3-yl)-3-(l] 
(benzopyran-4-one-3-yl)-2-propen-l-one (56) with phenylhydrazine. 
Formation of l-phenyl-3-(4-hydroxy-(lJbenzopyran-2-one-3-yI]-5-(5-
(2-hydroxyphenyl)-l-phenylpyrazoI-4-yI]-pyrazolin (58b). 
(2E)-1 -(4-hydroxy-1 -benzopyran-2-one-3-y l)-3-[ 1 ] (benzopyran-
4-one-3-yl)-2-propen-l-one 56 (1.0 gm, 2.7 mmole), phenylhydrazine 
(0.55 ml, 5.4 mmole) were taken in methanol (25 ml) and 5 drop of 
acetic acid were added to it. The reaction mixture was refluxed on water 
bath for 45 min. It was cooled at room temperature and poured into ice-
cold water (200 ml), filtered, washed with ethanol-water mixture, and 
dried. The yellow solid l-phenyl-3-[4-hydroxy-[l] benzopyran-2-one-3-
yl]-5-[5-(2-hydroxyphenyl)-1 -phenylpyrazol-4-yl]-pyrazolin 58b as 
obtained was recrystallized from chloroform-benzene; yield 53%; 
m.p.l85-190°C. 
Spectral Data: 
UV (DMSO) X niax : 283.15, 365.55 nm. 
IR(KBr)Vn,ax • 3614, 3452, 1710, 1610 and 1553 
cm"'. 
' H N M R ( 3 0 0 M H Z , DMS0-d6) : 5 3.74 (m, IH, Ha), 4.17 (m, HI, 
Hb), 5.2l(m, IH, He), 6.75-7.62 
(m, 17H, Ar-H), 7.45 (s, IH, Hd), 
8.04 (d, IH, J = 7.2Hz, H5"); 
MS (% rel int) 
Analyzed for C33 H24 N4 O4 
m/z 540 (M^, 90), 539 (50), 522 
(5), 496 (5), 463 (6), 447 (10), 420 
(5), 379 (5). 
Calculated C = 73.33, H = 4.44, 
N = 10.37%; Found C = 73.54, 
H = 4 .75 ,N= 10.55%. 
The reaction of (2E)-l-(4-hydroxy-l-benzopyran-2-one-3-yI)-3-(lJ 
(benzopyran-4-one-3-yI)-2-propen-l-one (56) with guanidine hydro 
chloride (59). 
Formation of 3-amino-l-(4-hydroxy-l-benzopyran-2-one-3-yl]-3-(l-
benzopyran-4-one-3-yl)-propen-l-one (60c'). 
(2E)-1 -(4-hydroxy-1 -benzopyran-2-one-3-y l)-3-[ 1 ] (benzopyran-
4-one-3-yl)-2-propen-l-one 56 (1.0 gm, 2.7 mmole), was dissolved in 
acetic acid (20 ml) and guanidine hydrochloride (0.51 gm, 5.4 mmole) 
and catalytic amount of sodium acetate (0.44 gm, 5.4 mmole) added to 
it. The reaction mixture was refluxed on an oil bath for 10 hrs, cooled 
and allowed to stand at room temperature to afford white solid 60c'. It 
was filtered, washed with water and dried. The filtrate was poured into 
ice-cold water (50 ml) to get more 60c'. The two solids were combined 
and recrystallized from chloform-methanol mixture to afforded 
3-amino-1 -(4-hydroxy-1 -benzopyran-2-one-3-yl]-3-( 1 -benzopyran-4-one-
3-yl)-propen-l-one 60c'; yield 66.2%; m.p.156-158 °C. 
Spectral Data: 
UV (MeOH) X 234 JS, 302.89 nm. 
IR (KBr) Vr 3437, 1686 and 1620 cm"'. 
'H NMR (300 MHz, CDCI3) 5 3.31 (dd, IH, Ha), 3.63 (dd, IH, 
Hb), 4.88 (m, IH, He), 8.45 (s, 
IH, H-2'), 8.27 (dd, IH, H-5'), 
7.99 (dd, IH, H-5'), 7.36-7.76 (m, 
3H, Ar-H). 
MS (% rel int) 
Analyzed for C21 H15 N 06 
m/z 377 (M^, 100), 333 (10), 257 
(5), 216 (5), 213 (5), 199 (5), 
171(5), 161 (10), 117(5), 120(5), 
92 (5). 
Calculated C = 66.84, H = 3.97, 
N = 3.71%; Found C = 67.10, 
H = 4.22, N = 3.85%. 
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Synthesis of 6,7-dimethyl-4-hydroxy-2-oxo-2H-l-benzopyran-3-carboxal 
dehyde (67). 
Triethylorthoformate (150 ml) was moist by adding water (20 ml) 
and shaking in a separating funnel. The aqueous layer was removed and 
organic layer was transferred to a 250 ml of round bottom flask. To this 
moist triethylorthoformate was added a catalytic amount of p-toluene 
sulfonic acid (100 mg) and heated on water bath for 0.5 hr. Now 6,7-
dimethyl-4-hydroxy-2-oxo-2H-l-benzopyran (5.0 gm) was added in 
portion with simultaneous thorough shaking of the content of the flask. 
After complete addition was made, the reaction mixture was refluxed for 
0.5 hr (completion of the reaction was checked by TLC).The reaction 
mixture was concentrated under reduced pressure and extracted with 
diethyl ether (40 ml). The ethereal layer was washed with water, dried 
over anhydrous sodium sulfate and concentrated. The residue, after 
evaporation of the ether was crystallized from the chloroform-petrol to 
give 6,7-dimethyl-4-hydroxy-2-oxo-2H-1 -benzopyran-3-carboxaldehyde 
67; yield 60%; m.p.MO^'C. 
The compound was identified on the basis of m.p., mixed m.p. and co-
TLC from an authentic sample. 
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The reaction of 4-hydroxy-2-oxo-2H-l-benzopyran-3-carboxaldchyde (31) 
with triacetic acid lactone (64). 
Formation of 3-acetoacetyIpyrano [3,2-c] [1] benzopyran-2,5-dione (68). 
4-Hydroxy-2-oxo-2H-l-benzopyran-3-carboxaldehyde 31 (1.0 gm, 
5.3 mmole) and triacetic acid lactone 64 (0.65 gm, 5.1 mmole) were taken in 
ethanol (20 ml) and refluxed on boiling a water bath for 0.5 hr. On cooling 
yellow solid of 3-acetoacetylpyrano [3,2-c] [1] benzopyran-2,5-dione 68 was 
obtained. It was filtered, washed with ethanol and purified by recrystallization 
from chloroform; yield 72%; m.p. 242-243 °C. 
Spectral Data: 
UV (MeOH) X niax : 230, 270, 385, and 410 nm. 
IR (KBr) v^ ax : 3500, 1760, 1730, 1640 and 1550 cm^ '. 
'H N M R (300 MHz, DMSO-dfi) : 5 2.30 (s, 3H, CH3), 7.11 (s, IH, H^), 
7.23-8.21 (m, 4H, Ar-H), 8.52 (s, 
lH,Hb), 10.5(brs, IH,). 
MS (% rel. int.) : m/z 298 (M^ 47), 283 (10), 270 (5), 
256 (10), 255 (10), 242 (20), 241 
(100), 213 (10), 185 (25), 120 (35) 
and 92 (30). 
Analyzed for C,6 HioOfi : Calculated C = 64.42, H = 3.35%. 
Found C = 64.53, H = 3.55%. 
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The reaction of 6,7-diniethyl-4-hydroxy-2-oxo-2H-l-benzopyran-3-
carboxaldehyde (67) with triacetic acid lactone (64). 
Formation of 8,9-dimethyl-3-acetoacetylpyrano |3,2-c] [1] bcnzo 
pyran-2,5-dione (69). 
A mixture of 6,7-dimethyl-4-hydroxy-2-oxo-2H-l-benzopyran-3-
carboxaldehyde 67 (1.0 gm, 4.5 mmole) and triacetic acid lactone 64 
(0.57 gm, 4.5 mmole) was taken in methanol (30 ml) and stirred at 60 "C 
for 3 hrs. A greenish yellow solid 8,9-dimethyl-3-acetoacetylpyrano 
[3,2-c] [1] benzopyran-2,5-dione 69 deposited. The crystals were 
filtered, washed with methanol and dried; yield 66.2%; m.p.240 °C. 
Spectral Data: 
UV (MeOH) X a^x : 236.57, 288.52, 340.47 nm. 
IR (KBr) Vmax 3377, 1756 and 1720 cm' . 
'H N M R (300 MHz, CDCI3) 5 2.27 (s, 3H, CH3), 2.38 (s, 3H, CH3), 
2.42 (s, 3H, CH3), 6.88 (s, IH, Ha), 
7.26 (s, IH, Ar-H), 7.84 (s, IH, Ar-
H), 8.91 (s, lH,Hb). 
MS (rel. int.) : m/z 327 (M"^  + 50), 326 (M^ 20), 311 
(10), 298 (5), 283 (10), 270 (35), 269 
(30), 241(20), 213 (10), 197 (15), 148 
(80), 128(15), 120(20). 
Analyzed for C,8 H,4 06 : Calculated C = 66.25, H = 4.29%; 
Found C = 66.40, H = 4.35%. 
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The reaction of 3-acetoacetylpyrano |3, Z-cJ [IJ benzopyran-2,5-dionc (68) 
with hydrazine hydrate. 
Formation of 3-(3-methyI pyrazol-5-yI)-pyrano (3, 2-c) (IJ benzopyran-2,5-
dione (70a). 
3-Acetoacetylpyrano [3, 2-c] [1] benzopyran-2,5-dione 68 (1.0 gm, 3.3 
mmole) was dissolved in acetic acid (20 ml) and hydrazine hydrate (1 ml, 20.2 
mmole) added to it. The reaction mixture was refluxed for 1 hr on an oil bath. 
On cooling light yellow solid 3-(3-methyl pyrazol-5-yl)-pyrano [3,2-c] [1] 
benzopyran-2,5-dione 70a was obtained. It was filtered, washed with water and 
dried. The filtrate was poured into crushed ice-water (50 ml) when more 70a 
was collected by filtration. The two solids were combined and purified by 
recrystallization from chloroform-benzene mixture as yellow shining needles; 
yield 70%; m.p. 135-140 °C. 
Spectral Data: 
UV (MeOH) X 258.58, 233.49, 211.74 nm. 
IR (KBr) V, 3250, 1767, 1711, 1628 and 1557 cm" 
'H N M R (300 MHz, CDCI3) 2.35 (s, 3H, CH3), 6.75 (s, IH, Ha), 
7.16-8.11 (m, 4H, Ar-H), 7.71 (s, IH, 
Hb), 8.61 (brs, NH). 
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MS (rel. int.) 
Analyzed for Ci6 Hio N2 O4 
: m/z 294 (M^ 20), 293 (20), 279 (5) 
253 (5), 161 (20), 153 (100), 137 (50), 
133(40), 120 (20) and 104(10). 
: Calculated C = 65.30, H = 3.40, 
N = 9.52%; Found C = 65.55, H = 
3.65, N = 9.72%. 
The reaction of 3-acetoacetyIpyrano [3, 2-c] [1] benzopyran-2,5-dione (68) 
with phenylhydrazine. 
Formation of 3-(3-methyl-l-phenyI pyrazoI-5-yI)-pyrano [3, 2-c] [1] benzo 
pyran-2, 5-dione (70b). 
3-Acetoacetylpyrano [3,2-c] [1] benzopyran 2,5-dione 68 (1.0 gm, 3.3 
mmole) was taken in acetic acid (20 ml) and phenylhydrazine (1 ml, 10.2 
mmole) added to it. The reaction mixture was refluxed for 1 hr on an oil bath. 
On cooling at room temperature a yellow solid was obtained. It was filtered, 
washed with water and dried. The filtrate was poured into crushed ice-water 
(50 ml) when more 3-(3-methyl-l-phenyl pyrazol-5-yl)-pyrano [3, 2-c] [1] 
benzopyran-2, 5-dione 70b was obtained. The two solids were combined and 
recrystallized from chloroform; yield 65%; m.p.225-230 °C. 
Spectral Data: 
UV (MeOH) X 
IR(KBr)v„ax 
208.40,373.64,367.31 nm. 
1760, 1726, 1637 and 1565 cm" 
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' H N M R (300 MHz, CDC13) 
MS (% rel. int.) 
Analyzed for C22 Hu N2 O4 
5 2.39 (s, 311, CH3), 6.59 (s. III, Ha), 
7.35-8.04 (m, 9H, Ar-H), 7.81 
(s, lH,Hb); 
m/z 370 (M^ 100), 369 (20), 329 (5), 
213 (5), 185 (10), 181 (5), 161 (30), 
157 (30), 153 (70), 137 (50), 133 (40), 
120(30), 104 (30) and 92 (35). 
Calculated C = 71.35, H = 3.78, 
N = 7.56%. Found C = 71.55, H = 
3.90, N = 7.70%. 
The reaction of 3-acetoacetyIpyrano [3,2-c] [1] benzopyran-2,5-dione (68) 
with hydrazinobenzothiazole. 
Formation of 3-(3-methyl-l-benzothiazolo pyrazol-5-yI)-pyrano 
(3,2-c] [1] benzopyran-2,5-dione (70c). 
3-Acetoacetyl pyrano [3,2-c] [1] benzopyran 2,5-dione 68 (1.0 gm, 3.3 
mmole) was dissolved in alcohol (25 ml) containing PTS in catalytic 
amount and hydrazinobenzothiazole (0.6 gm, 3.3 mmole) added to it. 
The reaction mixture was refluxed on boiling water bath for 16-18 hrs. It 
was cooled at room temperature to afford 3-(3-methyl-l-benzothiazolo 
pyrazol-5-yl)-pyrano [3,2-c] [1] benzopyran-2,5-dione 70c as light green 
crystalline solid. It was filtered, washed with alcohol and dried; yield 
72%; m.p.270-75 "C. 
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Spectral Data: 
UV (MeOH) X n,ax 208.40, 226.80, 248.54, 288.69, 
300.40 nm. 
IR (KBr) v„,ax 
'H N M R (300 MHz, CDCI3) 
MS (% rel. int.) 
Analyzed for C23 H,3 N3 O4 S 
1740, 1643, 1557, and 1442 cm'. 
5 2.40 (s, 3H, CH3), 6.50 (s, IH, Ha), 
8.01 (s, IH, Hb), 7.32-8.01 (m, 8H, 
Ar- H). 
m/z 427 (M\ 100), 399 (10), 383 
(20), 371 (10), 214 (5), 170 (5), 126 
(5). 
Calculated C - 64.63, H = 3.04, 
N = 9.83%; Found C = 64.72, H = 
3.15, N = 9.95%. 
The reaction of 3-acetoacetyIpyrano [3,2-cl [1] benzopyran-2,5-dione (68) 
with hydroxylammonium sulfate. 
Formation of 3-(3-niethyl isoxazol-5-yI)-pyrano [3,2-c] [1] benzopyran-2,5-
dione (70d). 
Hydroxylammonium sulfate (0.54 gm, 3.3 mmole) was dissolved in 15 
ml of water and 10 drops of dil HCl added to it. This solution was added to a 
solution of 3-acetoacetylpyrano [3,2-c] [1] benzopyran-2,5-dione 68 (1.0 gm, 
3.3 mmole) in acetic acid (12 ml). The reaction mixture was refluxed on an oil 
bath for 1 hr. The Pale yellow crystalline solid 3-(3-methyl isoxazol-5-yl)-
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pyrano [3,2-c] [1] benzopyran-2,5-dione 70d as obtained on cooling was 
filtered, washed with cold water and dried; yield 70%; m.p. 230 °C. 
Spectral Data: 
UV(MeOH)X„a, 
IR (KBr) V 
max 
'H N M R (300 MHz, CDCI3) 
MS (% rel. int.) 
206.72, 233.49, 283.67, 375.68 nm. 
1765, 1725, 1628, 1603, 1566 and 
1555 cm' 
5 2.40 (s, 3H, CH3), 6.98 (s, IH, Ha), 
7.44-8.14 (m, 4H, Ar- H), 8.67 (s, IH, 
Hb); 
m/z 295 {M\ 50), 254 (20), 213 (10), 
185 (10), 157 (100), 134 (75), 120 
(25), 106 (40) and 76 (30). 
Analyzed for C|6 H9 N Of Calculated C = 65.08, H = 3.05, 
N = 4.74%; Found C = 65.15, H = 
3.10, N = 4.78%. 
The reaction of 8,9-diinethyl-3-acetoacetylpyrano [3,2-c] [1] 
benzopyran-2, 5-dione (69) with hydrazine hydrate. 
Formation of 8,9-dimethyI-3-(3-niethylpyrazoI-5-yI)-pyrano [3,2-c] 
[1] benzopyran-2,5-dione (71a). 
8,9-Dimethyl-3-acetoacetylpyrano [3,2-c] [1] benzopyran-2, 5-
dione 69 (1.0 gm, 3.0 mmole) was dissolved in acetic acid (20 ml) and 
hydrazine hydrate (1 ml, 20.2 mmole) added to it. The reaction mixture was 
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refluxed for 1 hr on an oil bath. On cooling light yellow solid 8,9-diinethyl-3-
(3-methylpyrazol-5-yl)-pyrano [3,2-c] [1] benzopyran-2,5-dione 71a was 
obtained. It was filtered, washed with water and dried. The filtrate was poured 
into crushed ice water (50 ml) when more 71a was collected by filtration. The 
two solids were combined and purified by recrystallization ft-om chloroform-
benzene mixture as yellow shining needles; yield 65%; m.p. 315-320 °C. 
Spectral Data: 
UV (MeOH) X „,a> 
IR (KBr) V 
max 
' H N M R (300 MHz, DMSO-dfi) 
MS (% rel. int.) 
Analyzed for Cig H H N2 O4 
264.40,280.45, 310.60 nm. 
3215, 1746, 1721, 1630 and 1559 cm''. 
5 2.31 (s, 3H, CH3), 2.38 (s, 3H, 
CH3), 2.40 (s, 3H, CH3), 6.71 (s, 
IH, Ha), 8.42 (s, IH, Hb), 7.39 (s, IH, 
H-7),7.79(s, 1H,H-10). 
m/z 322 (M^ 85), 307 (80), 289 (65), 
279 (20), 242 (5), 238 (10), 198 (20), 
154(100). 
Calculated C = 67.08, H = 4.34, 
N = 8.69%; Found C = 67.25, H = 
4.55, N = 8.85%. 
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The reaction of 8,9-dimethyl-3-acetoacetylpyrano 13,2-c] |1) 
benzopyran-2, 5-dione (69) with phenylhydrazinc. 
Formation of 8, 9-dimethyi-3-(3-methyl-l-phenylpyrazoI-5-yl)-
pyrano [3,2-c] [l]benzopyran-2,5-dione (71b). 
8,9-Dimethyl-3-acetoacetylpyrano [3,2-c] [1] benzopyran-2, 5-
dione 69 (1.0 gm, 3.0 mmole) was taken in acetic acid (20 ml) and 
phenylhydrazinc (1 ml, 10.2 mmole) added to it. The reaction mixture was 
refluxed on an oil bath for 1 hr. On cooling at room temperature a yellow solid 
was obtained. It was filtered, washed with water and dried. The filtrate was 
poured into crushed ice-water (50 ml) when more 8, 9-dimethyl-3-(3-methyl-
l-phenylpyrazol-5-yl)-pyrano [3,2-c] [1] benzopyran-2,5-dione 71b was 
obtained. The two solids were combined and purified by recrystallization from 
chloroform as yellow crystals; yield 70%; m.p. 245-250 °C. 
Spectral Data: 
UV (MeOH) X 
IR (KBr) 
'H NMR (300 MHz, CDCI3) 
MS (% rel. int.) 
210.07, 235.16, 287.02, 370.66 nm. 
1748, 1721, 1635 and 1559 cm"'. 
6 2.34 (s, 3H, CH3), 2.39 (s, 6H, 
2CH3), 6.57(s, IH, Ha), 7.16- 7.81 
(m, 8H, Ar-H+H-6). 
m/z 398 (M\ 100), 397 (20), 370 
(10), 357 (5), 241 (5), 213 (5), 209 
(5), 189 (5), 185 (5), 181 (5), 165 
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Analyzed for C24 Hig N2 O4 
(10), 161 (5), 148(35), 132(10). 120 
(10). 
Calculated C = 72.36, H = 4.52, 
N = 7.03%; Found C = 72.50, H = 
4.74, N = 7.18%. 
The reaction of 8,9-dimethyl-3-acetoacetyIpyrano [3,2-c] [1] 
benzopyran-2, 5-dione (69) and hydrazinobenzothiazole. 
Formation of 8,9-dimethyI-3-(3-methyI-l-benzothiazoIopyrazol-5-
yl)-pyrano [3,2-c] [1] benzopyran-2,5-dione (71c). 
8,9-Dimethyl-3-acetoacetylpyrano [3,2-c] [1] benzopyran-2,5-
dione 69 (1.0 gm, 3.0 mmole) was dissolved in alcohol (25 ml) containing 
p-toluene sulfonic acid (30 mg) and hydrazinobenzothiazole (0.53 gm, 
3.0 mmole) added to it. The reaction mixture was refluxed on boiling 
water bath for 16-18 hrs. It was cooled at room temperature to afford 
8,9-dimethyl-3-(3-methyl-l-benzothiazolopyrazol-5-yl)-pyrano [3,2-c] 
[1] benzopyran-2,5-dione 71c as light green crystalline solid. It was 
filtered, washed with alcohol and dried; yield 66%; m.p. 285-290 °C. 
Spectral Data: 
UV (MeOH) X max 
IR (KBr) 
210.07, 288.69, 365.64 nm. 
1768, 1742, 1684 and 1640 cm" 
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'H N M R (300 MHz, CDCI3) 2.30 (s, 9H, 3CH3), 6.48 (s. IH, Ha), 
6.97-8.17 (m, 7H, Ar-H), 8.81 (s, IH. 
Hb). 
MS (% rel. int.) m/z 455 (M\ 100), 427 (10), 411 (5), 
399 (10), 321 (2), 308 (5), 153 (70), 
167(10), 123(3). 
Analyzed for C25 H,? N3 O4 S Calculated C = 65.93, H = 3.73, 
N = 9.23%; Found C = 66.12, H 
3.98, N = 9.35%. 
The reaction of 4-hydroxy-2-oxo-2H-l-benzopyran-3-carboxaldehyde (31) 
with 5,5-dimethyIcyclohexan-l,3-dione (72). 
Formation of 7-(4-hydroxycoumarin-3-yI)-10,10-diniethyl-8-oxo-8, 9, 
10, 11-tetrahydro pyrano [3,2-c] coumarin (74). 
A mixture of 4-hydroxy-2-oxo-2H-l-benzopyran-3-carboxaldehyde 
31 (1.0 gm, 5.3 mmole) and 5,5-dimethylcyclohexan-l,3-dione (dimedone) 72 
(0.72 gm, 5.1 mmole) was refluxed in ethanol (20 ml) for 1 hr. The cream 
coloured solid 7-(4-Hydroxycoumarin-3-yl)-10,10-dimethyl-8-oxo-8,9,10, 
11-tetrahydropyrano [3,2-c] coumarin 74 obtained on cooling, was filtered, 
washed with ethanol and purified by recrystallization from chloroform; yield 
60%; m.p. 240-245 °C. 
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Spectral Data: 
UV(MeOH)X, 
IR(KBr)v,„ax 
211.74, 258.58, 302.07 nm. 
1724, 1612, 1369, 1304, 1199, 1037 
and 754 cm -1 
'HNMR(300MHz,CDCl3) 5 1.11 (s, 3H, CH3), 1.18 (s, 3H, 
CH3), 2.36 (s, 2H), 2.38 (s, 2H), 5.113 
(s, IH), 7.17-7.94 (m, 6H, Ar-H), 8.04 
(dd, IH, H-5', J = 7.8, 1.2 Hz), 7.92 
(dd, IH, H-1, J = 7.8, 1.2 Hz), 10.55 
(brs, IH); 
M S (% rel. int.) 
Analyzed for C27 H20 O7 
m/z 456 (M^ 40), 335 (20), 307 (5), 
295 (100), 239 (25), 121 (4) and 107 
(10). 
Calculated C = 71.05, H = 4.38%; 
Found C = 71.23, H = 4.55%. 
The reaction of 4-hydroxy-2-oxo-2H-l-benzopyran-3-carboxaldehyde 
(31) with 3-methyI-l-phenyl-5-pyrazolone (76). 
Formation of methylidene-bis-4,4-(3-niethyl-5-oxo-l-phenylpyrazole) (78). 
4-Hydroxy-2-oxo-2H-l-benzopyran-3-carboxaldehyde 31 (1 gm, 5.3 
mmole) was dissolved in ethanol (15 ml) and 3-methyl-l-phenyl-5-pyrazolone 
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76 (0.9 gm, 5.2 mmole) added to it. The reaction mixture was relluxed for 10-12 
115 hrs. Yellow solid methylidene-bis-4, 4-(3-methyl-5-oxo-l-phenylpyrazole) 78 
as obtained on cooling was filtered, washed with ethanol and recrystallized from 
chloroform or benzene; yield 61.5%; m.p. 182-185 °C. 
Spectral Data: 
UV (MeOH) X 208.40, 332.18 nm. 
' H N M R ( 3 0 0 M H Z , CDCI3) 
MS (% rel. int.) 
IR(KBr)v,^ax 3350, 1627, 1592, 1550, 1498 and 
1328 cm-'. 
: 5 2.32 (s, 6H, CH3), 7.26-7.92 (m, 
IIH, Ar-H+ methylene proton). 
: m/z 358 (M^ 100), 357 (50), 340 (5), 
281 (6), 117 (4), 104 (4), 90 (20) and 
77 (35). 
: Calculated C = 70.39, H = 5.02, 
N = 15.64%; Found C = 70.15, 
H = 5.32, N = 15.25%. 
To refluxing moist triethylorthoformate (40 ml) containing a catalytic 
amount of p-toluene sulfonic acid was added 3-methyl-l-phenyl-5-pyrazolone 
76 (0.8 gm) in portions during 0.5 hr. The additions were so regulated that no 
solid remained before further addition was made. After complete addition the 
refluxing was continued for another 15 min., when yellow crystals of 
Analyzed for C21 Hig N4 O2 
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' H N M R (400 MHz, CDCI3) 
MS (% rel. int.) 
5 2.05 (s, 6H, 2CH3), 2.29 (s, 3H, 
CH3), 4.53 (s, IH, CH), 6.01 (s, 
2H, H-5), 7.068-7.62 (m, 5H, Ar-
H), 10.49 (s, IH, OH). 
m/z 418 ( M \ 50), 403 (5), 375 (5), 
245 (100), 262 (5), 156 (5), 137 
(5). 
Analyzed for C23 Hig N2 Oe Calculated C = 66.02, H = 4.30, 
N = 6.69%; Found C = 66.23, H = 
4.55, N = 6.40%. 
The reaction of 5-azido-3-methyI-l-phenylpyrazole-4-carboxaI 
dehyde (80) with triacetic acid lactone (64). 
Formation of 4-(4-hydroxy-6-methyl-2-oxo-2H-pyran-2-one-3-yl)-
3,7-dimethyI-l-phenylpyrazolo [3,4:2,3]-4H-pyrano [3,2-c] pyran-5-
one (95). 
5-Azido-3-methyl-l-phenylpyrazole-4-carboxaldehyde 80 (1.0 gm, 
4.4 mmole) was dissolved in methanol (20ml) and triacetic acid lactone 
64 (0.53 gm, 4.4 mmoles) added to it. The resultant mixture was refluxed 
on water bath for 6 hrs. It was concentrated and allowed to stand at room 
temperature when cream coloured solid crystallized out from the reaction 
mixture. It was filtered, washed with ethanol, dried and recrystallized 
from chloroform-benzene to afford 4-(4-hydroxy-6-methyl-2-oxo-2H-
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pyran-2-one-3-yl)-3,7-dimethyl-l-phenylpyrazolo [3,4:2,3]-4H-pyrano 
[3,2-c] pyran-5-one 95; yield 65.3%; m.p.230-32 °C. 
Spectral Data: 
UV (MeOH) X max 
IR (KBr) v^ax 
' H N M R (500 MHz, CDCI3) 
MS (% rel. int.) 
207.91, 265.23 nm. 
3378, 1703 and 1621 cm' 
5 2.15 (s, 6H, 2CH3), 2.31 (s, 3H, 
CH3), 5.13 (s, IH, CH), 5.93 (s, 
IH, H-5'), 6.20 (s, IH, H-5), 7.26 -
7.71 (m, 5H, Ar-H), 10.12 (br s, IH, 
OH, D2O exchangeable), 
m/z 418 (M^ 20), 292 (100), 137 
(50), 155(20). 
Analyzed for CzsHigNz 06 Calculated C = 66.02, H = 4.30, 
N = 6.69%; Found C = 66.23, H = 
4.55, N = 6.40%. 
Reaction of 5-chloro-3-methyI-l-phenyIpyrazoIe-4-carboxaldehyde 
(79) with 4-hydroxycoumarin (1). 
Formation of 4-(4-hydroxy-2-oxo-2H-l-benzopyran-2-one-3-yl)-3-
methyl-l-phenylpyrazolo [3,4:2,3]-4H-pyrano (3,2-b]-l-benzopyran-
5-one (96). 
To a solution of 5-chloro-3-methyl-l-phenylpyrazole-4-
carboxaldehyde 79 (1.0 gm, 4.5 mmole) and 4-hydroxycoumarin .1 (0.74 
gm, 4.5 mmole) in alcohol (20 ml) was added anhydrous sodium acetate 
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(0.37 gm, 4.4 mmole). The reaction mixture was refluxed on water bath 
for 18 hrs. It was then cooled at room temperature and poured into ice 
cold water. The white solid which precipitate out was filtered, 
washed with cold water, dried and recrystallized from DMF to 
give 4-(4-hydroxy-2-oxo-2H-l-benzopyran-2-one-3-yl)-3-methyl-l-
phenylpyrazolo [3,4:2,3]-4H-pyrano [3,2-b]-l-benzopyran-5-one 96 as 
white crystals; yield 74.3%; m.p. 270 °C. 
Spectral Data: 
UV(MeOH)^„3x 210.07, 246.87, 255.23, 308.76 nm. 
IR (KBr) V,,, 3451 and 1729 cm 1 
'H NMR (400 MHz, DMSO-de) 
MS (% rel. int.) 
5 2.62 (s, 3H, CH3), 4.75 (s, IH, 
CH), 7.25-7.79 (m, IIH, Ar-H), 
8.20 (d, 2H, J = 7.9 Hz). 
m/z491 (M^+1, 100), 317(90). 
Analyzed for C29 H,8 N2 Og : Calculated C = 71.02, H = 3.67, 
N = 5.71%; Found C = 71.35, H = 
3.95, N = 5.40%. 
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Reaction of 5-azido-3-inethyl-l-phenyipyrazole-4-carboxaldehydc 
(80) with 4-hydroxycoumarin (1). 
Formation of 4-(4-hydroxy-2-oxo-2H-l-benzopyran-2-one-3-yl)-3-
methyI-1-phenylpyrazolo [3,4:2,3]-4H-pyrano [3,2-cl-l-benzopyran-
5-one (97). 
A mixture of 5-azido-3-methyl-l-phenylpyrazole-4-
carboxaldehyde 80 (1.0 gm, 4.5 mmole) and 4-hydroxycoumarin 1 (0.71 
gm, 4.4 mmole) in methanol (20 ml) was refluxed on water bath for 2 
hrs and allowed to cool at room temperature. The solid which 
crystallized out from the reaction mixture, was filtered, washed with 
ethanol, dried and recrystallized from chloroform to give 4-(4-hydroxy-
2-OXO-2H-1 -benzopyran-2-one-3-yl)-3-methyl-1 -pheny Ipyrazolo 
[3,4:2,3]-4H-pyrano [3,2-c]-l-benzopyran-5-one 92 as white solid; yield 
70%; m.p. 290-292 °C. 
Spectral Data: 
UV (MeOH) >. max : 211.74, 246.87, 255.23, 325.49 nm. 
IR(KBr)v^a, : 3078, 1731 and 1670 cm"'. 
'H NMR (500 MHz, CDCI3) : 6 2.12 (s, 3H, CH3), 5.36 (s, IH, CH), 
7.30-7.83 (m, IIH, Ar-H), 7.97 (d, IH, 
H-5), 8.04 (d, IH, H-5). 
MS (% rel. int.) : m/z 490 (M^ 50), 489 (10), 369 (5), 
329 (55), 209 (5), 208 (5), 193 (5), 
167(5), 120(10), 90(15). 
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Analyzed for C29H,8N2 06 : Calculated C = 71.02, H - 3.67, 
N = 5.71%; Found C = 71.35, H = 
3.95, N = 5.40%. 
Synthesis of 5-ainino-3-methyl-l-phenyIpyrazole-4-carboxaldehyde (102). 
To a stirred solution of sodium borohydride (0.6 gm) in water (3 ml) 
were added 5-azido-3-methyl-l-phenylpyrazole-4-carboxaldehyde 80 (1.0 gm, 
4.5 mmole) and toluene (1 ml). The reaction mixture was stirred for 4-5 hrs at 
room temperature. A reddish brown solid was obtained after completion of the 
reaction. The solid was filtered, washed thoroughly with water and adsorbed on 
a column of silica gel. Elution of the column by a mixture of benzene-ethyl 
acetate (99:1 v/v) afforded 5-amino-3-methyl-l-phenyl pyrazole-4-
carboxaldehyde 102 as white solid; yield 60%; m.p. 110-112 °C (lit."*^  m.p. 92-
93 °C). 
The reaction of 5-amino-3-methyl-l-phenylpyrazole-4-carboxal 
dehyde (102) with triacetic acid lactone (64). 
Formation of 3,6-diniethyl-l,8-diphenyl-diazocino (3,4-c:7,8-c'] bis 
pyrazole (106). 
5-Amino-3-methyl-l-phenylpyrazole-4-carboxaldehyde 102 (1.0 
gm, 5.0 mmole) and triacetic acid lactone 64 (0.6 gm, 5.0 mmoles) were 
taken in pyridine (20 ml) and catalytic amount of piperidine (0.5 ml) 
added to it. The reaction mixture was stirred at room temperature for 48-
50 hrs. The reaction mixture was acidified with HCI and extracted 
with chloroform. The reaction mixture was concentrated and 
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chromatographed over silica gel. Elution of the column with benzene-
ethylacetate (90:10 v/v) afforded a white crystalline solid labeled as 3,6-
dimethyl-l,8-diphenyl-diazocino [3,4-c:7,8-c'] bis pyrazole 106; yield 
40.6%; m.p. 98 °C. 
Spectral Data: 
UV(MeOH)).,ax 
IR(KBr)v„,ax 
' H N M R (300 MHz, CDCI3) 
MS (% rel. int.) 
Analyzed for C22 Hig Ng 
206.12, 263.44 nm. 
1594 and 1550 cm"'. 
5 2.48 (s, 6H, 2CH3), 8.19 (s, 2H), 
7.34-7.65 (m, lOH, Ar-H). 
m/z 366 (M^ 15), 336 (10), 289 (15), 
275 (10), 260 (15), 183 (75), 182 (50), 
169 (15), 156 (10), 154 (50), 141 (15), 
128(20), 106(25), 102(10). 
Calculated C = 72.13, H = 4.91, 
N = 22.95%; Found C = 72.30, 
H = 5.18, N = 22.55%. 
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